Targeting retinoid receptors with dysregulated microNRAs in pancreatic duct adenocarcinoma by Yin, Shuai
Aus der Klinik für Allgemein-, Viszeral-, Gefäß- und Transplantationschirurgie der 
Ludwig-Maximilians-Universität München 
Direktor: Prof. Dr. Jens Werner 
 
 
 
 
Targeting retinoid receptors with dysregulated microNRAs in 
pancreatic duct adenocarcinoma 
 
 
 
 
Dissertation 
zum Erwerb des Doktorgrades der Medizin 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
 
vorgelegt von 
Shuai Yin 
aus Hefei, China 
2018 
 
 
 
Mit der Genehmigung der Medizinischen Fakultät 
der Universität München 
 
 
 
 
Berichterstatter: Prof. Dr. Jens Werner 
Mitberichterstatter: Prof. Dr. Max Schnurr 
 PD Dr. Sebastian Kobold 
Mitbetreuung durch den 
promovierten Mitarbeiter: 
                                             
Prof. Dr. Alexandr Bazhin                                        
    
    
    
    
Dekan: Prof. Dr. med. dent. Reinhard Hickel 
 
 
 
            
                                                     
Tag der mündlichen Prüfung: 04.10.2018
 
 
 
 
To my parents, for their unconditional love, endless support and encouragement 
 
 
I 
 
Declaration 
 
Yin, Shuai 
Lujiang Road.9 23/01 
230000, Hefei 
P.R. China 
 
I hereby declare, that the submitted thesis entitled 
 
“Targeting retinoid receptors with dysregulated microNRAs in pancreatic duct 
adenocarcinoma” 
is my own work. I have only used the sources indicated and have not made unauthorised use of 
services of a third party. Where the work of others has been quoted or reproduced, the source is 
always given. 
 
I further declare that the submitted thesis or parts thereof have not been presented as part of an 
examination degree to any other university 
 
             München, 10.2018                                   Yin, Shuai 
 
II 
 
ACKNOWLEDGMENTS ....................................................................................................................................... VII 
ABBREVIATIONS ................................................................................................................................................. VIII 
SUMMARY .................................................................................................................................................................. 1 
1. INTRODUCTION .................................................................................................................................................... 2 
1.1 CANCER ................................................................................................................................................................ 2 
1.1.1 Cancer statistics ............................................................................................................................................ 2 
1.1.2 Types of Cancer ............................................................................................................................................ 3 
1.1.3 The Biology of cancer ................................................................................................................................... 4 
(I) Sustaining Proliferative Signaling ................................................................................................................................... 5 
(II) Evading Growth Suppressors ......................................................................................................................................... 6 
(III) Avoiding immune destruction ....................................................................................................................................... 7 
(IV) Enabling replicative immortality .................................................................................................................................. 7 
(V) Induced and Sustained Angiogenesis ............................................................................................................................. 8 
(VI) Invasion and Metastasis ................................................................................................................................................ 9 
(VII) Tumor-Promoting Inflammation ................................................................................................................................ 10 
1.1.4 Genetics of cancer ....................................................................................................................................... 11 
1.1.5 Oncogene ..................................................................................................................................................... 11 
1.1.6 Tumor suppressor gene ............................................................................................................................... 12 
1.1.7 Tumor microenvironment ............................................................................................................................ 12 
 1.2 THE PANCREAS .................................................................................................................................................. 14 
III 
 
1.3 PANCREATIC DUCT ADENOCARCINOMA (PDAC) ................................................................................................ 15 
1.3.1 Epidemiology and Risk Factors of PDAC ................................................................................................... 16 
1.3.2 Genetic mutations in PDAC ........................................................................................................................ 19 
1.3.3 The microenvironment of PDAC ................................................................................................................. 20 
1.3.4 Aberrant signal pathways in PDAC ............................................................................................................ 22 
1.3.5 Subtypes of PDAC defined by gene mutation and global gene profiles ...................................................... 24 
1.4 RETINOIC ACID AND RETINOID RECEPTORS .......................................................................................................... 27 
1.4.1 The biology of retinoic acid and retinoid receptors .................................................................................... 27 
1.4.2 Retinoic acid response elements ................................................................................................................. 28 
1.4.3 RA signaling ................................................................................................................................................ 29 
1.4.4 Retinoid receptor and the PDAC ................................................................................................................ 33 
1.5 MICRORNAS ....................................................................................................................................................... 33 
1.5.1 The biology of microRNAs .......................................................................................................................... 33 
1.5.2 The complexity of gene regulations by miRNAs .......................................................................................... 35 
1.6 POTENTIAL MIRNAS TARGET OF RETINOID RECEPTORS ....................................................................................... 36 
2. SPECIFIC AIMS OF THE THESIS ..................................................................................................................... 37 
3. MATERIALS AND METHODS ........................................................................................................................... 38 
3.1 MATERIALS ......................................................................................................................................................... 38 
3.1.1 Instruments ................................................................................................................................................. 38 
3.1.2 Disposables ................................................................................................................................................. 39 
IV 
 
3.1.3 Chemicals and Reagents ............................................................................................................................. 40 
3.1.4 Kits .............................................................................................................................................................. 41 
3.1.5 Cell lines ..................................................................................................................................................... 41 
3.1.6 Antibodies ................................................................................................................................................... 42 
3.1.7 Medium and solutions ................................................................................................................................. 43 
3.1.8 Buffers ......................................................................................................................................................... 44 
3.1.9 miRNAs and Primers .................................................................................................................................. 45 
3.2 METHODS ........................................................................................................................................................... 47 
3.2.1 PDAC cell culture ....................................................................................................................................... 47 
3.2.2 HPDE cell culture ....................................................................................................................................... 48 
3.2.3 Freezing and thawing cells ......................................................................................................................... 48 
3.2.4 Cell counting ............................................................................................................................................... 49 
3.2.5 The isolation of microRNAs from cultured cells ......................................................................................... 50 
3.2.6 The isolation of RNA from cultured cells .................................................................................................... 51 
3.2.7 SYBR Green quantitative PCR for miRNAs ................................................................................................ 51 
3.2.7.1 cDNA synthesis for miRNA RT-PCR ..................................................................................................................... 51 
 3.2.7.2 Real time PCR analysis of mature miRNAs ......................................................................................................... 52 
3.2.8 SYBR Green quantitative PCR for retinoid receptor (RARA, RARB, RXRA, RXRB) .................................. 54 
3.2.8.1 cDNA synthesis of retinoid receptor mRNA .......................................................................................................... 54 
3.2.8.2 Real time PCR of retinoid receptor ......................................................................................................................... 55 
V 
 
3.2.9 Transfection of miRNAs .............................................................................................................................. 57 
3.2.10 Protein extraction ..................................................................................................................................... 58 
3.2.11 Protein quantification ............................................................................................................................... 58 
3.2.12 Protein gel electrophoresis (SDS-PAGE) .................................................................................................. 59 
3.2.13 Western blotting ........................................................................................................................................ 61 
3.2.13.1 Protein transfer ..................................................................................................................................................... 61 
3.2.13.2 Protein detection ................................................................................................................................................... 61 
3.2.14 Bioinformatic analysis of the miRNA target.............................................................................................. 62 
3.2.15 Statistics analysis ...................................................................................................................................... 62 
4. RESULTS ................................................................................................................................................................ 64 
4.1 PREDICTION OF RETINOID RECEPTORS TARGETED BY MIRNAS ............................................................................ 64 
4.2 INVESTIGATION OF MIRNAS TARGET SITES IN THE 3’UTR OF RETINOID RECEPTORS ........................................... 65 
4.3 INVESTIGATION OF THE EXPRESSION OF SELECTED MIRNAS IN PDAC AND HPDE CELL LINES .......................... 66 
4.4 ANALYSIS OF RETINOID RECEPTOR EXPRESSION IN PDAC CELL LINES ................................................................ 67 
4.5 CORRELATION ANALYSIS BETWEEN SELECTED MIRNAS AND RETINOID RECEPTORS ........................................... 69 
4.6 INVESTIGATION OF RETINOID RECEPTORS EXPRESSION AFTER THE MANIPULATION OF MIRNAS EXPRESSION ...... 72 
4.6.1 Investigation of the optimal transfection conditions ................................................................................... 72 
4.6.2 Analysis of protein expression of retinoid receptors after miRNA transfection .......................................... 74 
5. DISCUSSION ......................................................................................................................................................... 82 
5.1 ABERRANT LEVEL OF RETINOID RECEPTORS IN CANCER ...................................................................................... 82 
VI 
 
5.2 MECHANISM OF ABERRANT LEVEL OF RETINOID RECEPTORS IN PDAC ............................................................... 83 
5.3 ABERRANT EXPRESSION LEVEL OF MIRNA IN PDAC .......................................................................................... 84 
5.4 MIRNA PROFILES BY MICROARRAY IN PDAC ..................................................................................................... 86 
5.5 THE REGULATION OF RETINOID RECEPTORS BY MICRORNAS IN PDAC ............................................................... 87 
6. REFERENCE: ........................................................................................................................................................ 91 
7. CURRICULUM VITAE............................................................................................................................................89 
 
 
 
 
 
 
 
 
 
 
VII 
 
ACKNOWLEDGMENTS 
Foremost, I would like to express my sincere and deepest gratitude to my advisors Prof. Jens 
Werner and Prof. Alexandr Bazhin for the continuous support and guidance throughout my doctoral 
work, especially for their impressive motivation, constant enthusiasm, endless patience and 
immense knowledge. They provide me with great support in various ways. Above all and the most 
needed, they showed me the way to initialize and organize scientific research with complete 
independence and motivation in the present and my future scientific work.   
I would like to express my profound gratitude to Ines, for her kind help in many of the experiments 
in this work.  
I would like to give especial thanks to Anne, for her excellent help in dealing with the some results 
of the experiments.  
I also thank Sevdiye, Nicole, Maresa, Miachael, Beatrice, Nadine, Ute for their very kind help 
throughout my work. 
I express my gratitude to my fellow lab colleges: Taimuraz, Sara, Jingcheng, Daniel, Yike, Qian, 
David, Hao, Tong, Nikolas, Rami, Katharina and Tanja for all the funs we have had in the past 
years. 
 
To all the members in the lab - the kind place where I gained and grew up - thank you very much!    
 
Last but not the least, I would like to thank my family for supporting me spiritually throughout my 
life. 
 
VIII 
 
ABBREVIATIONS 
 
3’UTR 3’ untranslated region 
ATRA All-trans retinoic acid 
Bp Base pair 
BCA Bicinchoninic Acid 
BSA Bovine Serum Albumin 
CSCs Cancer Stem Cells 
CAF Cancer-associated Fibroblasts 
cDNA Complementary DNA 
dNTPs Deoxynucleotide Triphosphates 
DNA Deoxyribonucleic Acid 
DMSO Dimethyl Sulfoxide 
DMEM Dulbecco's modified Eagle's medium 
EMT Epithelial-Mesenchymal Transition 
EDTA Ethylene-diamine Tetraacetic Acid Disodium Salt 
ECM Extracellular Matrix 
FBS Fetal Bovine Serum 
g Gram 
IX 
 
g Gravity 
h Hours 
HPDE Human Pancreatic Duct Epithelial 
HCl Hydrogen chloride 
mRNA Messenger RNA 
MTA Methyltransferase 
µg Micro gram 
miR microRNA 
miRNA microRNA 
mg Milli gram 
m Minutes 
MAPK Mitogen-activated protein kinase 
TEMED N,N,N’,N’-Tetramethylenediamine 
ng Nano gram 
nM Nano Molar 
nt Nucleotides 
PDAC Pancreatic Duct Adenocarcinoma 
PanINs Pancreatic Intraepithelial Neoplasias 
PSCs Pancreatic Stellate Cells 
X 
 
PBS Phosphate Bffered Saline 
PI3K Phosphatidylinositol 3-kinase 
PAGE Polyacrylarnide Gel Electrophoresis 
PCR Polymerase chain reaction 
PVDF Polyvinylidene Difluoride 
Pre-miR Precursor microRNA 
qPCR Quantitative PCR 
qRT-PCR Quantitative RT-PCR 
RB retinoblastoma 
RA Retinoic Acid 
RARα / RARA Retinoic acid receptor alpha 
RARβ / RARB Retinoic acid receptor beta 
RARγ Retinoic acid receptor gama 
RARE Retinoic acid response element 
RXRα / RXRA Retinoic X receptor alpha 
RXRβ / RXRB Retinoic X receptor beta 
RXRγ Retinoic X receptor gama 
RR Retinoid receptors 
RT-PCR Reverse transcriptase- PCR 
XI 
 
RNA Ribonucleic Acid 
RISC RNA induced silencing complex 
RT Room temperature 
STAT3 Signal transducer and activator of transcription 3 
SDS Sodium Dodecyl Sulphate 
TAE Tris-acetate-EDTA 
VEGF Vascular Endothelial Growth Factor 
VEGFR Vascular Endothelial Growth Factor Receptor 
 
 
 
 
1 
 
Summary 
Retinoid (i.e., vitamin A, all-trans retinoic acid and other synthetic derivatives of vitamin A) 
induce cell differentiation and growth via the interaction of retinoid receptors in various normal 
and malignant cells. In addition to the success of all-trans-retinoic acid -based differentiation 
therapy in acute promyelocytic leukemia, emerging attempt in the combination of RA therapy and 
traditional chemotherapy has been studied in various solid cancer. Retinoid receptors (RARA, 
RARB, RXRA, and RXRB) and retinoic acid were reported to be down-regulated in pancreatic 
duct adenocarcinoma (PDAC) compared to normal pancreas. Moreover, the reduced expression of 
retinoid receptors correlates with the expression of these markers involved in the cell differentiation 
and the epithelial-mesenchymal transition. Further analysis revealed that the expressions of RARA 
and RXRB are associated with the overall survival in PDAC patients. Reduced level of retinoid 
and their receptors is associated with worse survival outcomes in PDAC patients. Yet, the 
mechanism of the down-regulation of retinoid receptors is not well defined. miRNA, as a class of 
small non-coding RNAs, can incorporate into the RNA-induced silencing complex and post-
transcriptionally regulate the mRNA expression typically by binding to the 3’ untranslated region 
(3’-UTR) of the complementary mRNA sequence. The aim of this study was to find out whether 
selected dysregulated miRNAs in PDAC are responsible for the decreased level of retinoid 
receptors. For this purpose, we first performed a bioinformatics research to reveal conserved target 
sequences for deregulated miRNAs within the 3’UTR region of retinoid receptor mRNA. Next, we 
investigated the expression of selected retinoid receptors and miRNAs in BxPC-3, DanG, 
MiaPaCa-2, Panc-1 cell lines and the Human Pancreatic Duct Epithelial (HPDE) cell line. Further, 
we investigated the expression level by manipulating the expression of selected miRNAs. We 
demonstrated that none of these miRNAs can target the selected retinoid receptors in vitro. 
Therefore, we conclude that dysregulated miR-138, miR-206, miR-613, miR-9 and miR-27a/b are 
not involved in the regulation of the expression of retinoid receptors in PDAC patients. 
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1. Introduction 
1.1 Cancer 
1.1.1 Cancer statistics 
    Cancer is a complex disease based on progressive accumulations of genetic aberrations and 
epigenetic changes of cells that escape from normal cellular control. Up to date, cancer constitutes 
an enormous burden of human health worldwide, among one of the most leading causes of disease-
related death in both developing and developed countries .  
 
 
Figure 1. Constitute of global cancer deaths. (Source: GLOBOCAN 2012)  
    In 2012, nearly 14.1 million new cancer cases were diagnosed. More than 8.2 million cases 
died from cancer, despite the amount of newly diagnosed cases of cancer still climbing yearly due 
to the growth and aging of the population. It is estimated in 2030, 23.6 million new cancer cases 
Lung cancer
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Colorectal cancer
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Pancreatic cancer
Other
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are to be diagnosed (Jemal et al., 2011). In less developed countries, rapidly increasing population 
and the adoption of lifestyle containing cancer-related risk, such as alcohol abuse, smoking, poor 
diet, physical inactivity, has further increased the incidence of cancer. Among these newly 
diagnosed cases, lung cancer is the most common cancer in men while breast cancer is most 
common in women in developing countries. In more developed countries, cancer with the highest 
incidence among men and women are prostate cancer and lung cancer, respectively. Cancer death 
in developing countries accounts for 65% of worldwide death, less than the percentage of their 
population. Percentages of cancer-related death worldwide (for both sexes) are shown in Figure 1. 
    Although cancer occurs based on genetic aberrations, understanding the chaos of cancer cell 
physiology is crucial to the illumination of the complexity of cancer. Over the past three decades, 
abundant new knowledge of cancer research has been gained for the better understanding of cancer 
and eventually the preparation for novel therapeutic strategy. Decades ago, pathologists have 
defined the pathological type of cancer in term of the cell type. The category of different cancer 
types is indicated in the following section. 
 
1.1.2 Types of Cancer 
    Tumors are classified into two broad categories depending on their aggressiveness: the benign 
and malignant tumor. The majority of primary tumors in humans are benign and innocuous, except 
in rare cases where the progression of these localized masses oppress important adjacent tissues 
and organs, or secrete an excessive hormone which causes a pathological status. For instance, 
benign brain tumor could press on adjoining structures when proliferating large enough, thus 
causing dysfunction of important nerve (Cook & Freedman, 2011). Another example is that 
pheochromocytoma can induce paroxysmal elevated blood pressure by high-level secretion of 
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catecholamines (Mann, 2008). Generally, deaths caused by benign tumors are much rarer compared 
to that by malignant tumors (Ostrom et al., 2016).  
    Malignant tumors that derived from epithelial cells are called carcinomas (e.g. cancer). 
Moreover, these carcinomas that only originate from glandular epithelial are called 
adenocarcinoma, while those arise from squamous epithelium in tissues like skin and the esophagus 
are termed as squamous cell carcinomas. Malignant tumors that arising from non-epithelial cells 
can be categorized into three groups. The first group is termed as sarcomas, representing those 
tumor cells derived from osteoblasts, myocytes, adipocytes and fibroblast. The second group of 
non-epithelial cancers is derived from those cells in the hematopoietic system like bone marrow，
resulting in an abnormal production of non-functional blood cell or lymphatic cell. The term 
leukemia refers to that the malignant cells developed from circulating hematopoietic cell, while 
lymphomas represent that those lymphoid lineages originated solid malignant tumor are likely 
found in lymph nodes. The third group of non-epithelial malignant tumors includes glioma, 
astrocytoma and ependymoma which developed from either central or puerperal nervous system. 
There are also other specific malignant tumor types, such as melanoma and malignant teratoma, 
belong to none of the group mentioned above (Herrington, 2014).  
 
1.1.3 The Biology of cancer  
    During the past several decades, rapid advances and numerous knowledge in cancer research 
have provided new insight into cancer biology. Among the most famous point views, Weinberg et 
al have raised the famous viewpoint that there are 10 crucial alterations in cancer cells which 
conclude malignant property of cancer: (i) sustaining proliferative signaling, (ii) evading growth 
suppressors, (iii) avoiding immune destruction, (iv) enabling replicative immortality, (v) tumor-
promoting inflammation, (vi) activating invasion and metastasis, (vii) inducing Angiogenesis, (viii) 
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genome instability and mutation, (ix) resisting cell death, (x) deregulating cellular energetics 
(Figure 2). The essence of these hallmarks of cancer cell will be described in following section 
respectively (Hanahan & Weinberg, 2011).  
 
Figure 2. Acquired capabilities of the tumor cells (Hanahan & Weinberg, 2011). 
 
(I) Sustaining Proliferative Signaling 
    Normal tissue cell controls their mitotic cycle by carefully orchestrating the dynamic level of 
multiple growth signals that are involved in the cell growth and cell division, thereby maintaining 
the homeostasis of the cell and the whole body. These growth signals function by binding to 
6 
 
different classes of signaling molecules: diffusible growth factors, extracellular matrix components 
and cell-to-cell adhesion molecules. Cancer cell, however, re-manipulates these signals and acquire 
the capability to sustain proliferative signaling in alternative ways.  
    The malignant cell can generate growth factor ligands itself and bind to cognate receptors, 
resulting in autocrine signals which facilitate the proliferative stimulation of the malignant cell 
independently (Hanahan & Weinberg, 2011). Alternatively, the malignant cell can interact with the 
normal cell in the tumor stroma to gain additional growth factors (Mao, Keller, Garfield, Shen, & 
Wang, 2013). Besides, the cancer cell is able to disrupt the normal negative feedback loops which 
operate to maintain the homeostatic status of various types of signaling. The mutation of oncogenic 
RAS gene, for example, results in a high level of cellular Ras-GTP and the abolishment of the 
negative feedback by Ras-GDP. The high level of Ras-GTP leads to sustained activation of 
proliferative signal pathways (Eser, Schnieke, Schneider, & Saur, 2014). However, the mechanisms 
that control the release of these mitogenic signals remain largely unknown. 
(II) Evading Growth Suppressors   
    In normal cells, a variety of growth factors collaborates with dozens of growth suppressors to 
ensuring a homeostasis balance. Two typical tumor suppressors, RB (retinoblastoma-associated) 
and TP53 proteins, cooperate to serve as the central cellular regulatory circuits that master the 
decisions of proliferation, senescence and the apoptotic process of cells (Sherr & McCormick, 
2002). The RB protein, in response to diverse extracellular signals, functions as a critical 
gatekeeper by deciding whether or not a cell should enter into its division cycle. Cancers with RB 
signal mutations, however, miss its control of cell cycle in cancer cells, thereby permitting 
sustaining proliferation of cancer cell. Whereas TP53 is a tumor suppressor mainly govern internal 
abnormality like damage of genome or abnormal metabolism status. TP53 protein is able to halt 
further cell-cycle progression until these abnormal conditions have been normalized, otherwise 
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induceing apoptosis if the damage of the cell is irreparable. In addition to tumor suppressor proteins, 
evasion from contact inhibition also matters in a variety of cancer types. In ensuing years, NF2 
gene and LKB1 epithelial polarity protein are discovered to be key regulators in cell-cell contact 
inhibition (Faubert et al., 2014; Martin-Belmonte & Perez-Moreno, 2012). These two proteins 
could both strengthen the adhesion of cell-cell attachment and suppress further cell proliferation 
when yielding confluent cell monolayer in vitro. In numbers of cancers, NF2 and LKB1 has 
represented the most frequently lost tumor suppressor proteins involved in cell contact inhibition.   
(III) Avoiding immune destruction  
    Immune surveillance denotes that the whole body is monitored by the sensitive immune 
system which is in charge of recognizing and obliterating the most of the incipient cancer cells. 
However, a fraction of cancer cells can escape the detection and eradication by the immune system. 
In recent years, the immune system has been indicated to operate as a significant barrier to tumor 
formation and progression. Interestingly, cancer cells that originally generated in immune deficient 
mice are often inefficient at initiating secondary tumors in syngeneic immune competent hosts, 
while cancer cells from tumors arising in immune competent mice are able to initiate transplanted 
tumors in both types of hosts (Teng, Swann, Koebel, Schreiber, & Smyth, 2008). This could be 
explained by ‘‘immune editing’’, indicating that the surviving cancer cells in immune competent 
host gained a capability to colonize into a new tumor mass when transplanted to a new host, while 
tumors originate from immune deficient mice lack of the select process of the host immune system 
(Smyth, Dunn, & Schreiber, 2006). 
(IV) Enabling replicative immortality 
    Another important ability of cancer cells is their unlimited replicative potential, compared 
with normal cells only going through a limited number of growth-division cycles. The senescence 
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and crisis have been two distinct barriers that are responsible for this limitation of normal cells. 
Senescence indicates a non-proliferative but viable state while crisis denotes cell death. A vast 
majority types of tumor cells cultured in vitro appear to be immortalized, suggesting that this 
limitless replicative ability was gained in vivo during tumorigenesis. Most evidence indicates that 
telomeres in cancer cells protect the ends of chromosomes, thereby enabling the capability of 
proliferation. 
    Telomeres locate in the end of chromosomes. They are composed of several thousand repeats 
of a short 6 bp sequence element. DNA polymerases are unable to completely replicate the 3’ends 
of chromosomal DNA, lead to every chromosome loses 50-100bp telomeric DNA from the ends 
during each S phase. The telomeres shorten progressively after cell cycle in normal cells, thus 
failing to protect the ends of chromosomal DNA from end-to-end fusions (Shay & Keith, 2008). 
Cancer cells, however, enjoy functional levels of telomerase enzyme which guarantees stable 
chromosomal DNA by replenishing the lost telomere repeat segments (Shay & Keith, 2008). In this 
way, the cancer cells acquire the ability of resistance to induction of both cell senescence and cell 
crisis/apoptosis.  
(V) Induced and Sustained Angiogenesis   
    Angiogenesis, the tumor-associated neo-vasculature which is important for the acquirement 
of nutrients, oxygen as well as the evacuation of metabolic waste, is carefully regulated by pro-
angiogenic and anti-angiogenic factors. Cancer, when the growth of which is beyond 1–2 mm 
diameter, can interact with the hypoxic microenvironment to guide the sprouting of blood vessels 
from surrounding tissues into the tumor (Nishida, Yano, Nishida, Kamura, & Kojiro, 2006). A 
variety of cells within the cancer stroma, such as tumor-associated fibroblasts, macrophages, mast 
cells and CD11b+Gr1+ myeloid cells, participate in the complex angiogenesis signal networks in 
cancer. One of the well-known angiogenesis inducers and inhibitors are vascular endothelial 
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growth factor-A (VEGF-A) and thrombospondin-1 (TSP-1), respectively. VEGF ligand triggers the 
angiogenesis signaling via its binding to receptor tyrosine kinases (VEGFR-1–3) which are 
regulated by both hypoxia and oncogene signaling (Fong, 2008). However, TSP-1 serves as an anti-
angiogenic factor which binds to trans-membrane receptors in endothelial cells and therefore 
counterbalances pro-angiogenic effect. Generally, tumor angiogenesis is characterized by 
precocious capillary sprouting, excessive vessel branching, distorted and enlarged vessels, erratic 
blood flow, microbleeds, leakiness and aberrant levels of endothelial cell proliferation and 
apoptosis. 
(VI) Invasion and Metastasis 
    During the progression of cancer, primary cancer cells grow gradually beyond adjacent tissue 
and spread to distant sites to establish new tumor colonies. So far, cancer related death are of more 
than 90% caused by such metastasis. This kind of invasion-metastasis cascade is organized by a 
sequence of independent steps: (1) Local invasion of cancer cells through surrounding extracellular 
matrix (ECM) and stromal cell layers, (2) Intravasation of cancer cells into nearby blood and 
lymphatic vessels, (3) Survival and transition of cancer cells through the vasculature, (4) Arrest of 
cancer cells at distant organ sites, (5) Extravasation of cancer cells from vessels into the 
parenchyma of distant tissues, (6) Survival and colonization of cancer cells in metastasis site. These 
complex events are orchestrated by not only molecular pathways within cancer cells but also multi-
level interactions between cancer cells and stroma cells.  
    In order to invade the stroma, cancer cells must first detach from epithelial sheets with 
acquired highly motility and invasiveness. To overcome the E-cadherin-mediated intercellular 
junctions that knit together epithelial cell sheets and other barriers, carcinoma cells undergo a cell-
biological program known as the epithelial-mesenchymal-transition (EMT) (Seton-Rogers, 2016). 
During the EMT process, cancer cells break down cell-cell adhesion and tight junctions, followed 
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by the change of cell polarity which exhibits mesenchymal morphology and unregulated 
invasiveness. Specifically, the cancer cells undergo EMT begin to produce fibronectin, an 
extracellular matrix protein that is normally produced by mesenchymal cells such as the fibroblast. 
The expression changes of fibronectin and N-cadherin thus affects the organization of cells’ 
intermediate filament cytoskeleton and mortality. A set of important transcriptional factors, 
including Snail, Slug, Twist, and ZEB1/2, coordinates to manage the EMT of cancer cells. These 
transcription factors directly repress expressions of E-cadherin which maintain epithelial states. 
Besides, certain miRNAs belonging to miR-200 family could promote epithelial phenotypes by 
repressing ZEB1 and ZEB2 EMT-inducing transcription factors (Park, Gaur, Lengyel, & Peter, 
2008). Moreover, cancer cells can secrete matrix metalloproteinase (MMPs) to degrade ECM 
elements like IV collagen, laminin and vitronectin. Stroma cells like fibroblasts and myofibroblasts, 
endothelial cells, adipocytes, mesenchymal stem cells, as well as macrophages and other immune 
cells also determine the invasion and metastasis ability of cancer cells. These stromal cells are 
capable of improving aggressive behaviors of carcinoma cells via various signaling. For example, 
stromal CD4+ T-lymphocytes stimulate tumor-associated macrophages (TAMs) to trigger 
epidermal growth factor receptor (EGFR) signaling in the carcinoma cells and thus promoting 
mammary carcinoma invasion (Mao et al., 2013). In fact, only a small minority of disseminated 
cancer cells can finally succeed in terms of metastatic colonization and clinically detectable 
metastases. 
(VII) Tumor-Promoting Inflammation 
    Pathologists noticed that virtually every neoplastic lesion was infiltrated with immune cells at 
densities ranging from subtle infiltrations to gross inflammations. This was initially viewed as a 
systematic immune response of the host to eliminate tumor cells. However, recent evidence 
revealed that immune cell infiltrations could unanticipated enhance tumorigenesis and tumor 
progression in the way of providing various bioactive molecules (DeNardo, Andreu, & Coussens, 
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2010). Those factors include growth factors, survival factors, pro-angiogenic factors, extracellular 
matrix-modifying enzymes and EMT inductive signals. In addition, inflammatory cells can release 
reactive oxygen species which accelerate the evolution speed of tumor cells towards more 
malignancy status (Chaffer, San Juan, Lim, & Weinberg, 2016). 
 
1.1.4 Genetics of cancer 
    The genome of cancer is based on a constant succession of alterations at multiple levels 
ranging from subtle mutation to chromosomal lesions. Certain mutant genotypes ensure survival 
advantage of sub-clones of cancer cells, facilitating their growth dominance in a local tissue 
environment. Normal cells have DNA-maintenance system that keeps genomic integrity and 
induces genetically damaged cells to either senescence or apoptosis. In order to acquire mutant 
genes, cancer cells increase their rates of gene mutation which enable them to escape from the 
DNA-maintenance system. Inductions of genetic alterations of several critical genes determine 
different fate of the cells. Cell that harbors hundreds of these susceptible cancer gene experiences 
spontaneous mutation at a very low speed all the time. These critical genes can determine the fate 
of cancer cells and they are divided into two categories: tumor suppressor gene and oncogene (You 
& Jones, 2012). 
 
1.1.5 Oncogene 
    Oncogene is the gene that can stimulate growth, division and survival of cells. The abnormal 
activation of oncogene will lead to eventual immortalization or transformation of cells. Oncogenes 
with non-activated state existing in all normal cells are called proto-oncogenes. Namely, products 
of proto-oncogenes can induce cell mutations under abnormal activation. The activations of proto-
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oncogenes include retroviral transduction or retroviral integration, point mutation, insertion 
mutation, gene amplification, chromosomal translocation and protein-protein interaction. So far 
more than hundred oncogenes, like KRAS and Myc, are reported (Croce, 2008). 
 
1.1.6 Tumor suppressor gene 
    Tumor suppressor gene functions as ‘‘caretakers’’ of the cell damage. The functions of this 
tumor suppressor gene comprise: (1) Detecting and repairing DNA damage, (2) Inactivating or 
preventing mutagenic molecules before they have damaged the DNA, (3) Preventing unrestrained 
cellular growth, (4) Promoting cell cycle checkpoint activation (E. Y. Lee & Muller, 2010). Among 
the most important tumor suppressor genes are TP53, BRCA1/2, APC and RB1 gene. Up to date, 
more than 200 tumor suppressor genes are identified in human and other species (E. Y. Lee & 
Muller, 2010). 
 
1.1.7 Tumor microenvironment 
    In ensuing years, it is emphasized that tumor is more than simple aggregations of proliferating 
tumor cells. Instead, cancer is comprised of multiple different cell types as well as distinct stromal 
elements that participate in complex interactions with other elements. This viewpoint reveals that 
the biology of the tumor should be no longer understood as the simple accumulation of the traits 
of the cancer cells, but instead should encompass the contributions of the ‘‘tumor 
microenvironment’’ (Visvader & Lindeman, 2008). The tumor microenvironment represents the 
surviving environment of cancer which is constructed during the course of multistep tumorigenesis. 
As mentioned above, cancer cells with clonal heterogeneity comprise of cells with various degrees 
of differentiation, proliferation, vascularity, inflammation and invasiveness. Accumulated evidence 
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in recent years revealed a new subclass of neoplastic cells within tumors, termed as cancer stem 
cells (CSCs) (Visvader & Lindeman, 2008). More and more human tumors are found to contain 
such subpopulation with the properties of CSCs, which exert their efficient tumor-initiating 
capabilities in vivo experiment. In recent years, researchers have also interrelated the acquisition 
of CSC features with the EMT progression. The EMT of some cancer cells in certain models could 
induce defining features of CSC, such as self-renewal ability. Moreover, cells with properties of 
CSC are shown, in a variety of cancers, to be more resistant to commonly used chemotherapeutic 
and radiotherapeutic treatments.  
 
 
Figure 3. Cells in tumor microenvironment. Adjusted from (Hanahan & Weinberg, 2011) 
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    Besides, CSCs display their ability of cell dormancy, in which way they keep quiescent and 
survive from diverse therapy. In this case, dormant CSC turned to proliferate again in one time 
after the clinical termination of radiotherapy or chemotherapy. What’s more, several other cell types 
within stromal, such as endothelial cells, cancer-associated macrophage, immune inflammatory 
cells, also participate in the complex network to regulate the proliferation, migration and invasion 
of cancer cells (Mao et al., 2013). 
  
1.2 The pancreas  
    The pancreas is comprised of the exocrine pancreas and the endocrine pancreas. The exocrine 
pancreas mainly regulates digestion while endocrine pancreas is responsible for glucose 
metabolism. Acinar cells locate in the exocrine pancreas and constitute the most part of the 
pancreatic tissue. Acinar cells are organized as acini structure which consists of several hundreds 
of acinar cells. Adjacent acinar cells are linked by numerous gap junctions that allow intercellular 
communication. Acini is the smallest termini of the branching duct system. It secretes a variety of 
enzyme mixture, together with mucous and bicarbonate produced by duct cells, into the main 
pancreas duct and then empties into the duodenum. 
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Figure 4. Anatomy of pancreas (Bardeesy & DePinho, 2002). (a) Gross anatomy of the pancreas. (b) The exocrine 
pancreas. Adjusted from (Bardeesy & DePinho, 2002) 
 
    Another function of the pancreas is the regulation of blood glucose level, which is regulated 
by endocrine pancreas. There are totally four cell types (A-, B-, PP and δ-cells) which are arranged 
within the islets in the endocrine pancreas. Specialized hormones generated by these cells are 
secreted into the bloodstream. For example, A- and B-cells regulate the glucose level by the 
production of glucagon and insulin, respectively. While PP cell and δ-cells can produce pancreatic 
polypeptide and somatostatin to modulate the secretory properties of the other pancreatic cell types 
(Bardeesy & DePinho, 2002). Normal function of the pancreas is crucial for the body to maintain the 
homeostasis of metabolism. 
  
1.3 Pancreatic Duct Adenocarcinoma (PDAC) 
    PDAC is the fourth most common cause of cancer-related death in western countries, with a 
quite low 5 years survival rate. PDAC frequently eludes detection at its early stage due to diagnostic 
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limitations and the lack of specific symptoms in the early stage of the disease. Up to date, surgery 
still serves as the main treatment for PDAC patients who are under potentially curative resection. 
Despite, adjuvant chemotherapy and radiotherapy are emerging as potential options that could 
improve the survival in PDAC patients (Kamisawa, Wood, Itoi, & Takaori). Gemcitabine 
monotherapy or the systemic chemotherapy are recommended as the first option for these patients 
with locally advanced, unresectable PDAC. Chemotherapy strategies like “FOLFIRINOX” or 
“gemcitabine plus albumin-bound paclitaxel” represent the main strategy for the treatment of 
metastatic PDAC (M. A. Tempero et al., 2010). However, no remarkable progress, despite the 
toxicity of therapy, are achieved in terms of long-term survivals due to the intensive resistance of 
PDAC to a variety of therapy strategy. 
 
1.3.1 Epidemiology and Risk Factors of PDAC 
    PDAC is diagnosed mainly in the elderly population with the median age of 71 years. In 
western countries, PDAC is the fourth most common cause of death from cancer both in men (after 
lung, prostate and colorectal cancer) and women (after lung, breast and colorectal cancer) (M. 
Tempero, Malafa, & Hawary, 2016). In 2015, nearly 367,000 new cases of pancreatic cancer were 
diagnosed worldwide. In the United States, black individuals are found to suffer from the disease 
more often (12–15 cases per 100,000 men and 8–10 cases per 100,000 women) than their white 
counterparts. A higher incidence rate was recorded in high-income countries, so is that of urban 
populations higher than rural populations. The lowest rates were recorded in India, Northern and 
Central Africa (<2 cases per 100,000 men and 1 case per 100,000), which is probably due to the 
quality of diagnosis despite the difference of involved risk factors). Recent statistics and prediction 
model show the incidence will continue to climb in the United Kingdom and in North America (M. 
Tempero et al., 2016).  
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    The survival rate correlates closely with the tumor stages at the time of diagnosis. Specifically, 
the 5-year survival rate of stage IA pancreatic cancer is about 14% and stage IB cancer is about 
12%. While 5-year survival rate of stage IIB pancreatic cancer reaches to only 5%, compared with 
the rate of stage IIA cancer 7%. Stage III and stage IV PDAC patients has a 5-year survival rate of 
about 1%-3%. ("Pancreatic Cancer Survival Rates, by Stage," 2016.3.14) 
 
 
Variable Approximate Risk 
Risk factor  
             Smoking 2–3 
              Long-standing diabetes mellitus4 2 
              Nonhereditary and chronic pancreatitis 2–6 
              Obesity, inactivity, or both 2 
              Non–O blood group 1–2 
Genetic syndrome and associated gene or genes - %  
              Hereditary pancreatitis (PRSS1, SPINK1)  50 
              Familial atypical multiple mole and melanoma 
              syndrome (CDKN2A/p16)  
10–20 
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              Hereditary breast and ovarian cancer syndromes 
              (BRCA1, BRCA2, PALB2)  
1–2 
              Peutz–Jeghers syndrome (STK11/LKB1)  30–40 
              Hereditary nonpolyposis colon cancer (Lynch 
              syndrome) (MLH1, MSH2, MSH6)  
4 
              Ataxia–telangiectasia; 
              Familial pancreatic cancer (monoallelic) (ATM)  
Unknown 
              Li–Fraumeni syndrome (P53)  Unknown 
 
Table 1. Risk Factors and Inherited Syndromes Associated with Pancreatic Cancer (Kamisawa et al.). 
 
    There is a variety of risk factors that associate with PDAC incidence (Table 1). Although the 
definitely genetic basis of the disease heredity is unknown, almost 5% to 10% of PDAC origin 
from the family with a pancreatic cancer history. The patients’ relative risks of developing 
pancreatic cancer increase by factor 2, 6 and 30 with one, two and three family members surfed 
from pancreatic cancer compared with general population, respectively. Besides, general oncogenic 
factors like smoke, obesity, diabetes and chronic pancreatitis also increase the risk of PDAC 
(Kamisawa et al.). 
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1.3.2 Genetic mutations in PDAC 
    PDAC develops from pancreatic intraepithelial neoplasias (PanINs) and subsequent 
progressive stages of neoplastic growth. The most frequently altered genes in PDAC include KRAS, 
CDKN2A, TP53 and SMAD4.  
    Mutation of KRAS gene is usually the first genetic change that occurs in the mouse model of 
PDAC, detected in about 30% of early lesions. In PDAC patients, KRAS was found mutated in 
more than 90% cases (M. A. Tempero et al., 2010). Activated mutations of RAS-family oncogenes 
result in remarkable changes of cellular effects, including the induction of abnormal proliferation, 
survival and invasion through the stimulation of several effectors pathways such as epidermal 
growth factor (EGF) family (Ardito et al., 2012).  
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Figure 5.  Genetic alterations of PanIN progression model and frequencies of mutations in DPAC patients (Kamisawa 
et al.). 
    The mutation of CDKN2A, an important tumor suppressor gene, is detected in 80–95% PDAC 
patients. Loss of CDKN2A gene occurs frequently in moderately advanced lesions with features of 
dysplasia. The mutation of CDKN2A also exists in patients diagnosed with the familial atypical 
mole-malignant melanoma (FAMMM) syndrome, who have a 13-fold increased risk to develop 
pancreatic cancer (Ardito et al., 2012). 
    The TP53 tumor-suppressor gene is also frequently mutated in more than 65% of PDAC, 
usually in the way of missense alterations of the DNA binding domain. TP53 mutations arise in 
later-stage PanINs which has already acquired significant features of dysplasia with mutations of 
KRAS and CDKN2A. This mutation facilitates the genetic instability which leads to consistent 
genomic re-arrangements which are characterized by frequent aneuploidy, cytogenetic re-
arrangements and intratumoral heterogeneity.  
    DPC4/SMAD4 mutation serves as another key contributor for the development of PDAC. 
SMAD4 gene is inactivated in nearly 55% of PDAC, usually in the way of homozygous deletion 
and intragenic mutation. This gene encodes a protein that plays crucial roles in the transforming 
growth factor-beta (TGF-B)–mediated growth inhibitory pathway (Makohon-Moore & Iacobuzio-
Donahue, 2016).  
  
1.3.3 The microenvironment of PDAC 
    The microenvironment of PDAC is characterized by an abundant and compact collagenous 
stroma, resulting in an elevated interstitial fluid pressure and considerable hypoxic environment 
for cancer cells. PDAC stroma is mainly composed of extracellular matrix (ECM) proteins — 
collagens, fibronectin, laminin and non-collagenous proteins such as glycoproteins, proteoglycans 
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and glycosaminoglycans (Gore & Korc, 2014). The over-expression and deposition of these 
proteins in the interstitial results in high-level internal pressures which can reach 100 mmHg by 
the creation of a large gel-fluid phase. This unique microenvironment results in the robust fibro-
inflammatory response, widespread vascular collapse and hypoperfusion, which lead to the primary 
resistance of chemotherapy.  
    The ECM in PDAC is mainly produced by activated pancreatic stellate cells (PSCs), which 
have also been termed as cancer-associated fibroblasts (CAFs). PSCs are crucial for the remodeling 
of PDAC microenvironment. They can interact with cancer cells, as well as other stromal cells like 
immune cell and endothelial cells, facilitating the progression of PDAC. PSCs have been initially 
identified to inhibit cancer cell apoptosis and promote cell survival and resistance to chemotherapy 
by facilitating the niche formation of CSCs. Other cellular components in the stroma comprise of 
infiltrating immune cells, endothelial cells and neuronal cells. The fact that CD4+ regulatory T 
cells are infiltrated in the stroma suggests that the PDAC microenvironment is immune suppressive. 
This feature has generated the therapeutic attempt to target factors that mediate the immune 
suppression, such as PD-L1 (Hamanishi et al., 2016).  
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Figure 6. Activated pancreatic stele cells in PDAC. Adjusted from (Jorg Kleeff, 2016) 
    Up to date, it is still controversial whether and how the stroma participates in cancer 
progression. Contradictory results from in vitro experiment and in vivo trail make it more 
complicated (Gore & Korc, 2014). 
 
1.3.4 Aberrant signal pathways in PDAC 
    In PDAC, a variety of alterations in signaling pathways is reported in the past decades. In 
2008, Jones et al and his colleges have systemically investigated the genome and whole transcripts 
in 28 PDAC patients. They found that each of these cancers contains an average of 63 genetic 
alterations, which can be further grouped and categorized into 7 most important cellular signaling 
pathways and processes. These pathways are involved in modulating the hallmarks of cancer cells 
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as well as remodeling the stroma (Table 2) (Jones et al., 2008). For example, over-expression of 
multiple ligands in the tumor context can bind to EGFR, HGFR, HER2 or HER3 and result in 
elevated activation of RAS protein (Eser et al., 2014). Moreover, excessive activation of oncogenic 
RAS protein leads to sustained activation of downstream signaling pathways, such as mitogen-
activated protein kinase (MAPK) signaling, signal transducer and activator of transcription 3 
(STAT3), phosphatidylinositol 3-kinase (PI3K) and AKT signaling (Eser et al., 2014). Activated 
MAPK serves as a nuclear transcriptional factor that can induce, among others, the hypoxia-
inducible transcription factor 1A (HIF1A), which is regularly induced in respond to hypoxia in 
pancreatic cancer. HIF1A can, in turn, induce the expression of vascular endothelial growth factor 
A (VEGFA) which can promote angiogenesis and glucose metabolism. Similarly, TGFB binds with 
II TGFB receptor (TGFBRII) homodimer to activate type I TGFB receptor (TGFBRI) homodimer. 
This leads to the subsequent phosphorylation of nuclear transcriptional factors SMAD2, SMAD3 
and SMAD4 (Ikushima & Miyazono, 2010). Besides, mutation of CDKN2A results in enhanced 
mitogenic activities by increasing cyclin D1, CDK4 and CDK6 activity. Moreover, loss of RB1 
protein communicates with TGFB to activate non-canonical signaling pathways including MAPK, 
PI3K and WNT7B signaling (Ikushima & Miyazono, 2010).  
 
Regulatory pathway 
genetically altered 
Number of 
genetically 
altered genes 
detected 
Fraction of tumors with genetic 
alteration of at least one of the 
genes 
Representative altered 
genes 
 
 
Hedgehog signaling 19 100% TBX5, SOX3, LRP2, 
GLI1, GLI3, BOC, 
BMPR2, CREBBP 
Integrin signaling 24 67% ITGA4, ITGA9, ITGA11, 
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LAMA1, LAMA4, 
LAMA5, FN1, ILK 
C-Jun N-terminal kinase 
signaling 
9 96% MAP4K3, TNF, ATF2, 
NFATC3 
KRAS signaling 5 100% KRAS, MAP2K4, 
RASGRP3 
Small GTPase–dependent 
signaling (other than KRAS) 
33 79% AGHGEF7, ARHGEF9, 
CDC42BPA, DEPDC2, 
PLCB3, PLCB4, RP1, 
PLXNB1, PRKCG 
TGF-b signaling 37 100% TGFBR2, BMPR2, 
SMAD4, SMAD3 
Wnt/Notch signaling 29 100% MYC, PPP2R3A, WNT9A, 
MAP2, TSC2, GATA6, 
TCF4 
Table.2 Core signaling pathways and processes genetically altered in the majority of pancreatic cancers. (Jones et al., 
2008) 
 
1.3.5 Subtypes of PDAC defined by gene mutation and global gene profiles   
    Emerging genomic technologies have been applied to analyze whole gene profiles in either 
PDAC tissues or cells. Genomic investigation of global gene mutations and expression provides 
new insight to understand the cancer genetics and biology. Genomic analysis of PDAC could also 
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serve as the basis of precision medicine in the future.  
 
 
Figure 7. Three PDAC subtypes generated by microarray data sets using the PDAssigner gene set (Collisson et al., 2011). 
 
    In 2011, Collison et al have integrated the analysis of transcriptional profiles of primary 
PDAC specimens along with human and mouse PDAC cell lines. They defined three PDAC 
molecular subtypes with gene signatures: classical, quasi-mesenchymal, exocrine-like, with the 
therapeutic response and clinical outcome varying quite different (See Figure 7) (Collisson et al., 
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2011). 
 
 
Figure 8. Molecular subtypes of pancreatic cancer defined by Grimmond et al (Bailey et al., 2016). RNA-seq of 
pancreatic cancer identified 4 PDAC classes: squamous (blue); ADEX (abnormally differentiated endocrine-exocrine; 
brown); pancreatic progenitor (yellow); and immunogenic (red).  
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    Another group has also perform integrated genomic analysis of PDAC tissues from 456 PDAC 
patients (Bailey et al., 2016). They categorized 32 frequently mutated genes into 10 tumorous 
pathways: KRAS, TGF-B, WNT, NOTCH, G1/S transition, chromatin modification, SWI-SNF, 
ROBO/SLIT signaling, DNA repair and RNA processing. Based on these aberration signal 
pathways, four subtypes were subsequently identified: (1) Squamous; (2) Pancreatic progenitor; (3) 
Immunogenic; and (4) Aberrantly differentiated endocrine exocrine (ADEX) (Figure 8) (Bailey et 
al., 2016). Each subtype of PDAC patients was suggested with different treatment strategies. 
Moreover, the PDAC with different molecular subtypes could response differently to therapy. 
 
1.4 Retinoic acid and retinoid receptors 
1.4.1 The biology of retinoic acid and retinoid receptors 
    Retinoic acid, the metabolite of vitamin A, is important for growth and differentiation of both 
healthy and cancerous cells. All-trans retinoic acid (ATRA), the major physiologically active form 
of vitamin A, regulate the expression of many genes. Recently, retinoic acid and its derivatives are 
reported that they are able to inhibit proliferation and migration of various cancer types including 
PDAC (Garattini, Bolis, Fratelli, Paroni, & Terao, 2016; Guan et al., 2014; Kalitin & Karamysheva, 
2016; Y. Zhang et al., 2013). Disturbances of vitamin A metabolism are prevalent in various cancer 
types. Previous studies showed that concentration of ATRA and ATROL are reduced in PDAC 
cancer tissues compared to normal pancreatic tissue (Bleul et al., 2015).  
    Physiological effects of retinoid are mainly mediated by two families of nuclear receptors: the 
retinoic acid receptor (RAR) and the retinoid X receptor (RXR). RAR and RXR are bothe ligand-
dependent transcription factors. They belong to the nuclear hormone receptor superfamily. RAR 
and RXR family comprise several isotypes: RARA, RARB, RARγ and RXRA RXRB, RXRγ. 
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RARA, RXRA and RXRB are found ubiquitously expressed in human, while the others have tissue-
specific expressions. The A-, B- and γ-isotype of RAR can be activated by all-trans RA and 9-cis 
RA, while RXR-A,-B and -γ are mainly activated by 9-cis RA. Activated nuclear receptors are able 
to form the hetero- or homodimer (RAR/RAR and RAR/RXR). RXR can also dimerize with other 
receptors like the vitamin D3-receptor (VDR), thyroid hormone receptor (TR), peroxisome 
proliferator-activator receptor (PPAR) and orphan receptors. However, retinoid receptors regulate 
gene transcription mainly, under physiological conditions, by the formation of RAR/RXR 
transcriptional complexes (Amann, Eichmuller, Schmidt, & Bazhin, 2011; Evans & Mangelsdorf, 
2014; Urvalek, Laursen, & Gudas, 2014).  
 
 
Figure 9. The schematic functional domain of the retinoid receptor (Amann et al., 2011). Retinoic acid receptors consist 
of six domains, termed A-F, with independent functions. AF-1 contains several phosphorylation consensus sites for 
cyclin-dependent- and MAP kinases. The C domain is highly conserved and functions as the DNA-binding domain. 
The D domain promotes the steric conformation of the DNA-binding domain and interacts with transcriptional co-
regulator. E domain is the ligand binding domain. 
 
1.4.2 Retinoic acid response elements 
    Retinoic acid response element (RARE) is the specific sequence within many promoters. Both 
RAR-RXR heterodimers and individual retinoid receptor can recognize and bind to the RARE 
sequence. In addition, direct repeats (DR) of RARE with a space of two to five nucleotides (DR2-
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DR5) are also involved in the binding with homodimers of RXR. The dimerization partners of RXR 
can be RXR itself (for DR1), RAR (for DR1, DR2 and DR5), VDR (for DR3), PPAR (for DR1) 
and other receptors. The number of the combinatorial interaction of these receptors can be enlarged 
by changing their polarity and bind alternatively to the upstream or downstream of the DR. Such 
polarity reversion is important for switching the activity of the receptor heterodimer from an 
activator to a repressor of the retinoid-responsive gene (le Maire et al., 2012). 
 
1.4.3 RA signaling 
    Transcriptional effects of activated retinoid receptors are achieved by following steps: (i) 
Ligand binding, (ii) Receptors dimerization, (iii) DNA binding, (iv) Recruitments of co-activators 
and (v) The transcriptional modulation of the gene (Balmer & Blomhoff, 2002).  
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Figure 10. RA signaling. RA binds to RAR–RXR heterodimer to form complex which further bound to RAREs in the 
target gene, resulting in the control of gene transcription (Amann et al., 2011). 
 
    In the absence of RA, the receptor complex assembled by retinoid receptors and co-repressors 
N-CoR and SMRT can bound to the RARE sequence of target genes and repress the gene 
expression. However, the complex undergoes conformational changes upon RA binding, leading 
to the release of co-repressors and meanwhile the recruitment of co-activators to form an activator 
complex with histone acetyltransferase, methyltransferase (MTA) and kinases (Grosshans & 
Chatterjee). Co-activators possess a leucine-rich LXXLL motif while co-repressors share an 
L/IXXI/VI motif. Importantly, some co-activators share an interactive domain with each other, 
indicating their cooperativeness of gene regulation. Chromatin is decondensed after the co-
activator complex binding with the RARE region, thereafter p160 coactivators dissociate and the 
retinoid receptors complex start to recruit the transcriptional enzyme, including RNAPol II and 
general transcription factors which in turn increase chromatin remodeling at the promoter regions 
(Amann et al., 2011).  
    Retinoid receptors are nuclear receptors functioning as a part of transcription factors which 
play important role in a variety of cellular events. The diverse complex formed by these receptors, 
such as heterodimeric complex RAR-RXR, homodimerized RXR-RXR or RXR dimerized with 
another receptor such as PPAR, functions as a key transcriptional factor in retinoic acid signaling 
and other related signaling pathways.  
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Table 3. Up- or down-regulated genes regulated by retinoic acid and retinoid receptor directly or indirectly (Balmer & 
Blomhoff, 2002). 
 
    It is estimated that more than 532 downstream genes can be regulated by retinoic acid and 
retinoid receptor, either in the direct or the indirect way (see Table 3) (Balmer & Blomhoff, 2002). 
For example, 133 genes were strongly identified as being regulated directly, of which 63 were up-
regulated and 30 was variably regulated. The total number unregulated genes by retinoid and RA 
was 311. Interestingly, other 221 genes were either down-regulated or variably regulated (Balmer 
& Blomhoff, 2002). Besides, RA also acts on non-tumorous cells to affect the PDAC cells. RA was 
reported to induce quiescence and reduces motility of PSCs, and thus inhibiting proliferation and 
promoting apoptosis of surrounding PDAC cells (Balmer & Blomhoff, 2002).  
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Figure.11 Classification of genes regulated by retinoic acid and retinoid receptors. Differentially genes (>1.5 fold 
change) regulated by RR and RA were categorized based on known or predicted functions. 
 
    Pathway enrichment analysis of genes regulated by retinoid receptors and retinoic acid shows 
that these genes are widely involved in a variety of cellular events. Responsive genes encoded 
transcriptional factors involved in biological processes, such as metabolic processes, cell-cell 
junctions and organismal systems development. In addition, retinoid signaling can affect lots of 
other signaling pathways like PI3K-Akt signaling pathway, p53 pathway and Wnt pathway (Figure 
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11) (GSE69850, GSE69844 and GSE71856).  
    
1.4.4 Retinoid receptor and the PDAC 
    Disturbances of retinoic acid metabolism and dysregulation of retinoid receptors are very 
common in some types of cancer. We previously investigated the retinoids level in human and 
murine PDAC tissues using mass spectrometry and real-time RT-PCR analysis (Bleul et al., 2015). 
Moreover, the survival of PDAC patients was estimated using Kaplan–Meier method and Cox 
proportional hazards analysis. The analysis showed that the concentration of ATRA and all-trans 
retinol is significantly reduced in PDAC tissue compared to their normal counterparts in both 
human and mouse. The expressions of RARA, RARB, RXRA and RXRB are also significantly 
down-regulated in PDAC tissues. More importantly, the reduced expression of retinoid receptors 
correlates with the expression of markers of the EMT and stemness of cancer cell. Besides, the 
expression of RARA and RXRB is found to be associated with a better overall survival in PDAC 
patients. Accordingly, the reduced level of retinoids and their receptors is an important feature of 
PDAC (Bleul et al., 2015). However, the mechanism of the down-regulation of retinoid receptors 
is not well defined. 
 
1.5 microRNAs 
1.5.1 The biology of microRNAs 
    Genes can be regulated on various levels, such as epigenetic regulation (e.g. histone 
modifications, DNA methylation), transcriptional control (e.g. promoter regulation by transcription 
factors) or translational control by non-coding RNAs. MiRNAs are small non-coding endogenous 
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RNAs that are involved in multiple biological processes. These regulatory elements are first 
transcribed and then processed by Dicer and Drosha complexes into 21–23nt mature miRNAs (van 
Kouwenhove, Kedde, & Agami, 2011).  
 
 
Figure 12. Mechanism of blocking gene expression by mature miRNA. A precursor hairpin-shaped pre-miRNA is 
sliced to form a mature miRNA, which binds to the 3' untranslated region (3' UTR) of a target gene's mRNA and blocks 
its translation (Lin He & Hannon, 2004). 
 
    The miRNA is incorporated into the RNA-induced silencing complex (RISC), regulating 
posttranscriptional mRNA expression typically by binding to the 3’ untranslated region (3’-UTR) 
of the complementary mRNA sequence. The binding of RISC with mRNA is able to induce the 
cleavage or repression of gene translation (van Kouwenhove et al., 2011). Due to the significance 
of miRNAs, it has provided a new horizon to better understand the regulation of important 
oncogene or tumor suppressor gene in cancer. 
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1.5.2 The complexity of gene regulations by miRNAs 
    Gene regulation by miRNAs is previously thought to be simple, by binding to the 3’UTR as 
the canonical pathway. However, non-canonical binding and targeting have also been reported 
(Helwak, Kudla, Dudnakova, & Tollervey, 2013). For instance, recent CLASH (cross-linking, 
ligation, and sequencing of hybrids) analysis has revealed that although the majority miRNAs bind 
to 3’UTR, they can also bound to 5’UTRs, gene bodies, long non-coding RNAs (lncRNAs) as well 
as introns (Helwak et al., 2013). Moreover, the binding of miRNAs with promoters of genes could 
result in either gene repression or gene activation. The activation of genes is usually caused by the 
active histone marks (H3K4 trimethylation), compared with gene repression which is induced by 
H3K9 dimethylation (Helwak et al., 2013). 
    Depending on the orientation, two strands of the microRNA generated from pre-miRNAs are 
termed as 5p and 3p. Studies have shown that both strands can function as mature miRNAs in gene 
regulation. For example, both 5p and 3p of miR-142 and miR-17 can be incorporated into the RISC 
complex to regulate the gene expression (Kasashima, Nakamura, & Kozu, 2004; X. Yang et al., 
2013). Interestingly, both miR-17-5p and miR-17-3p are able to target the same gene TIMP3 which 
induce prostate cancer cell growth (X. Yang et al., 2013). However, there are also cases that 5p and 
3p produced by the same pre-miRNAs target two different genes. In the colorectal cancer cell, for 
instance, overexpression of miR-28-5p and miR-28-3p lead to different effects (Almeida et al., 
2012). Specifically, miR-28-5p altered the expression of CCND1 and HOXB3, whereas miR-28-
3p regulate the expression of NM23-H1. Another interesting point about the complexity of miRNA 
is that one single miRNA can, based on experimental and computational analysis, target hundreds 
or potentially thousands of mRNA molecules. So far, it is still hard to predict the regulation effect 
of miRNAs due to the fact that expression of different targets could be repressed to different 
degrees by a given miRNA. Hence, it seems impossible to predict the effects of miRNA on gene 
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expression at the global level. Lastly, due to the fact that cells, organs and human body function as 
a uniform organism, miRNAs can only target transcripts that were induced in a particular 
pathological context. Hence, specific genes that could be regulated by miRNAs in one cell type is 
largely dependent on the whole transcription of that particular cell under given conditions. That is 
to say, functional target relationship in one cell type does not necessarily prove to be the same 
effective in a different cell type. For example, Blodin et al showed that the function of miR-146a 
was almost exclusively restricted to the hematopoietic system (Bustin et al., 2013; Zhao et al., 
2011). This is vital for the prediction of the target and effect of miRNA manipulation across 
different cell types and tissue types. Hence, miRNA and mRNA interaction studies should be 
interpreted according to the specific cell type and the origin of tissue. 
 
1.6 Potential miRNAs target of retinoid receptors 
    Using online database, our preliminary analysis of the miRNA expression signature of PDAC 
has revealed some novel miRNA – candidates. We found that these miRNAs are potentially 
upregulated in PDAC tissue, suggesting that these miRNAs are candidate onco-miRNAs. Using in 
silico analysis, we identified several dysregulated miRNAs that could potentially target retinoid 
acid signal pathway. These miRNAs, namely miR-138, miR-206, miR-613, miR-9, miR-27a/b, 
miR-10a/b, are predicted to target at least one of these retinoid receptors (RARA, RARB, RXRA 
and RXRB). 
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2. Specific Aims of the Thesis 
    The present study aims to identify novel oncogenic-suppressive miRNAs as the regulator of 
retinoid receptors in PDAC. Towards this end, the study will be conducted with the following 
specific objectives: 
(1) To investigate the expression of retinoid receptors and miRNAs (miR-138, miR-206, miR-
613, miR-9, miR-27a/b, miR-10a/b) in PDAC cells and HPDE cell in vitro. 
(2) To investigate the expression of expression of retinoid receptors after the manipulation of 
the expression of these miRNAs and retinoid receptors. 
(3) To identify the relevance of target miRNAs in migration and invasion of PDAC cell if any 
of these retinoid receptors are targeted by selected miRNAs. 
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3. Materials and Methods 
3.1 Materials  
3.1.1 Instruments 
 
Instrument Company 
Centrifuge Eppendorf 
CO2 incubator (37℃) Thermo Fisher 
Water bath Grant 
Light microscope Olympus 
StepOne Real-Time PCR Systems  Applied Biosystems 
Pipetboy Gilson 
Pipettes Eppendorf 
Sterile work bench Hera Safe Thermo Electron 
Trans Blot Semi-Dry Electrophoretic transfer Cell Bio-Rad laboratories 
Vortexer VWR analog Vortex mixer 
Pipette holder Accu-jet® Pro 
Odyssey system LI-COR 
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3.1.2 Disposables 
 
Name Company 
24- well plate Corning 
96- well plate Corning 
6-well plate Corning 
Barrier sterile pipette tips Avant Guard 
Extra thick Blotting paper Bio-Rad 
Falcon tubes (15ml, 50ml) BD 
Cell culture dishes (10cm2) CellStar ® Grenier Bio-One 
Plastic pipettes (2, 5, 10, 25ml) CellStar ® Grenier Bio-One 
PVDF membrane (0.45um) Millipore 
Pipette tips TipOne (STARLAB) 
Cell culture flask BD 
MicroAmp Optical 96-Well Reaction Plate Thermo Fisher 
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3.1.3 Chemicals and Reagents 
 
Name Company 
Agarose Gibco BRL 
Ampicillin Sigma 
Chloroform Sigma 
Isopropyl alcohol Sigma 
Ethanol Sigma 
0.4% Trypan blue solution Sigma 
Dimethyl Sulfoxide (DMSO) Sigma 
Protein Ladder (1Kb) BioRad 
Ethylenediaminetetraacetic acid (EDTA) Sigma 
TEMED Sigma 
Hydrogen chloride (HCl) VWR BDH Prolabo 
Isopropanol Merck 
Methanol Sigma Aldrich 
Protease inhibitor tablets Roche 
Odyssey® Blocking Buffer LI-COR 
Tween 20 Roth 
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Sodium dodecyl sulfate (SDS) SERVA 
Ammonium Persulfate  Sigma 
 
3.1.4 Kits 
 
Kits Company 
HiperFect transfection kit Qiagen 
RNeasy Mini Kit Qiagen 
miScript II RT Kit Qiagen 
miScript SYBR Green PCR Kit Qiagen 
QuantiTect Reverse Transcription Kit Qiagen 
QuantiTect SYBR Green PCR Kits  Qiagen 
QuantiTect Primer Assays Qiagen 
miScript Primer Assays Qiagen 
QIAzol Lysis Reagent Qiagen 
BCA Protein Assay Reagents Peirce 
 
3.1.5 Cell lines 
Cell lines used in the study are listed in the following table: 
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Cell line Origin  Source  Culturing medium 
MiaPaCa-2 Pancreatic adenocarcinoma ATCC PRMI+10%FBS 
DanG Pancreatic adenocarcinoma ATCC PRMI+10%FBS 
Panc-1 Pancreatic adenocarcinoma ATCC PRMI+10%FBS 
BxPc-3 Pancreatic adenocarcinoma ATCC PRMI+10%FBS 
HPDE Normal human pancreatic duct 
epithelial  
Gift, Dr. Kong Bo 
(TUM, Germany) 
Keratinocyte Basal 
Medium + supplied 
supplements 
 
3.1.6 Antibodies 
 
Antibody Company 
Anti - MET antibody  Sigma 
Anti-RARA antibody Santcruz 
Anti-RARB antibody Santcruz 
Anti-RXRA antibody Santcruz 
Anti-RXRB antibody Santcruz 
Anti-RARA antibody CST 
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Anti-RARB antibody CST 
Anti-RXRA antibody CST 
Anti-RXRB antibody CST 
IRDye® 680LT Goat anti-Mouse LI-COR 
IRDye® 800CW Donkey anti-Rabbit LI-COR 
IRDye® 680CW Goat anti-Rabbit LI-COR 
IRDye® 800CW Donkey anti-Mouse LI-COR 
Protein ladder   Bio-Rad 
Anti-c-met antibody CST 
 
 
3.1.7 Medium and solutions 
 
DMEM, high glucose Gibco BRL 
Keratinocyte culture Medium Gibco 
Fetal Bovine Serum (FBS) Gibco BRL 
L-Glutamine Sigma 
Phosphate Buffered Saline (PBS) Gibco 
PRMI 1640 Medium Gibco BRL 
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Trypsin-EDTA solution 0.25% Sigma 
RIPA buffer Sigma 
 
 
3.1.8 Buffers 
 
 
Sample Buffer 58mM Tris, pH 6.8 
1.67% SDS 
5% Glycerol 
0.00025% Bromophenol Blue 
Separating Gel buffer 30% acrylamide mix 
1.5 M Tris-HCl, pH 8.8 
10% SDS 
10% APS 
Stacking gel buffer 30% acrylamide mix 
0.5 M Tris-HCl, pH 6.8 
10% SDS 
10% APS 
SDS-PAGE running buffer 25mM Tris 
250mM glycine, pH 8.3 
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0.1% SDS 
Transfer buffer 25mM Tris base 
192mM glycine 
0.01% SDS 
20% Methanol 
Tris-acetate-EDTA (TAE) buffer 40mM Tris 
20mM acetic acid 
1mM EDTA 
Washing buffer (PBS-T) 1000ml PBS 
0.1% Tween 20 
Blocking buffer Alternative 
1. Odyssey Blocking Buffer 
2. Washing buffer + 5% milk powder 
 
3.1.9 miRNAs and Primers 
All miRNAs products are purchased from Qiagen 
 
miRNA mimic or inhibitors        Sequence 
Syn-hsa-miR-9-5p miScript miRNA Mimic 5'UCUUUGGUUAUCUAGCUGUAUGA 
Syn-hsa-miR-27a-3p miScript miRNA Mimic 5'UUCACAGUGGCUAAGUUCCGC 
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Syn-hsa-miR-27a-5p miScript miRNA Mimic 5'AGGGCUUAGCUGCUUGUGAGCA 
Syn-hsa-miR-27b-3p miScript miRNA Mimic 5'UUCACAGUGGCUAAGUUCUGC 
Syn-hsa-miR-27b-5p miScript miRNA Mimic 5'AGAGCUUAGCUGAUUGGUGAAC 
Anti-hsa-miR-9-5p miScript miRNA Inhibitor 5'UCUUUGGUUAUCUAGCUGUAUGA 
Anti-hsa-miR-27a-3p miScript miRNA 
Inhibitor 
5'UUCACAGUGGCUAAGUUCCGC 
Anti-hsa-miR-27a-5p miScript miRNA 
Inhibitor 
5'AGGGCUUAGCUGCUUGUGAGCA 
Anti-hsa-miR-27b-3p miScript miRNA 
Inhibitor 
5'UUCACAGUGGCUAAGUUCUGC 
Anti-hsa-miR-27b-5p miScript miRNA 
Inhibitor 
5'AGAGCUUAGCUGAUUGGUGAAC 
miRNA negative control Oligos  
Hs_miR-9_1 miScript Primer Assay  
Hs_miR-27a_1 miScript Primer Assay  
Hs_miR-27b_2 miScript Primer Assay  
Hs_miR-138_1 miScript Primer Assay  
Hs_miR-206_1 miScript Primer Assay  
Hs_miR-613_1 miScript Primer Assay  
Hs_RARA_1_SG QuantiTect Primer Assay  
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(QT00095865) 
Hs_RARB_1_SG QuantiTect Primer Assay 
(QT00062741) 
 
Hs_RARG_1_SG QuantiTect Primer Assay 
(QT00000987) 
 
Hs_RXRA_1_SG QuantiTect Primer Assay 
(QT00005726) 
 
Hs_RXRB_1_SG QuantiTect Primer Assay 
(QT00061117) 
 
Hs_RXRG_1_SG QuantiTect Primer Assay 
(QT00007238) 
 
 
3.2 Methods 
3.2.1 PDAC cell culture 
    PDAC cell lines were maintained as a monolayer. Prior to cell culture, trypsin and media were 
warmed up in a 37℃ water bath. Cells were cultured in the Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cell was 
incubated at 37℃ in a humidified atmosphere of 5% CO2/95% air. Cells were passaged as the 
growth reach the confluence of 80% - approximately 1 or 2 times per week. Specifically, the 
medium was removed first. Cells were then washed with PBS and treated with trypsin. The same 
amount of complete medium was added to stop the digestion. Cells suspension were pelleted with 
a 200 × g centrifugation for 5–10 minutes and the supernatant was discarded. Then additional 
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complete growth medium was added to the flask and 10% of the suspension was transferred into 
each new flask. The flask was then supplemented with appropriate medium to make a 10-15ml 
total volume.  
 
3.2.2 HPDE cell culture 
    Immortalized Human Pancreatic Duct Epithelial cells (HPDE) was a kind gift from Dr. Bo 
Kong in Technical University of Munich (who get the cell from Prof. M.S. Tsao in Ontario Cancer 
Institute (Toronto, Canada)). HPDE cell line was maintained in Keratinocyte Basal Medium 
supplied with additional supplements (Lonza, Clonetics KBM, Cat#CC-3111). The flask was 
incubated at 37℃ in a humidified atmosphere of 5% CO2/95% air. Culture medium was replaced 
every two to three days following the general procedure of cell culture. Cells were passaged as the 
growth reach the confluence of 80%, following the same procedure applied in PDAC cell culture. 
 
3.2.3 Freezing and thawing cells 
    For the freezing procedure, cells were first trypsinized and centrifuged at 200 × g for 5 minutes 
and the growth medium was then discarded. The cells were then resuspended in freezing medium 
(90% FBS and 10% DMSO) and distributed into sterile vials for cell freezing. Vials containing the 
cells were immediately placed on ice, then allowed to freeze at -20℃ for 3 hours and then at -80℃ 
overnight. Vials were then transferred to liquid nitrogen for long-term storage. 
    For the thawing procedure, working steps should be done quickly to ensure a high proportion 
of the survival rate of the cells from the frozen state. Specifically, the frozen vial was immediately 
placed into a 37°C water bath. Cells inside the vials were then quickly thawed (< 1 minute) by 
gently swirling the vial in the 37°C water bath. Then the vial was transferred to a 15ml falcon tube 
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in a laminar flow hood. Then 10 ml pre-warmed complete growth medium was transferred into the 
falcon tube dropwise. After a centrifugation of the cell suspension at approximately 200 × g for 5–
10 minutes, the supernatant was carefully removed without disturbing the cell pellet. Cells were 
then gently resuspended in an approximate volume of complete growth medium and transferred 
into the cell culture flask. Cells were cultured in the incubator under normal conditions as 
mentioned before. 
 
3.2.4 Cell counting  
    Cells were counted using a hemocytometer. Briefly, equal volumes of single cell suspension 
and 0.4% trypan blue solution (with the volume ratio 1:1) were mixed together in a 1.5 ml tube. 
Trypan blue is a dye which stains only dead cells, thus live cells were unstained and visualized. 
The chamber of the hemocytometer was filled with the stained cell suspension by capillary action.  
 
Figure 13. Cells counting with hemocytometer (Neubauer). Cells stained with trypan were loaded onto the 
hemocytometer and the total number of cells in the four big squares (shown with blue numbers) was counted. The 
number of cells/ml of cell suspension is then calculated as described. 
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    The total number of cells in the four marked squares (Figure 13) was counted using a 
microscope. Each chamber of the hemocytometer is divided into nine 1.0mm squares. The chamber 
was then covered with a cover glass. So that the total volume over each square is 0.0001ml (0.1cm 
× 0.1cm × 0.1cm). Since 1cm^3 is equivalent to 1mL, the cell concentration per ml will be the 
average count per square × 2 (dilution factor) × 10^4. 
 
3.2.5 The isolation of microRNAs from cultured cells 
    Total miRNA from cells was isolated using QIAzol (Qiagen) following the manufacturer’s 
instruction (miRNeasy Mini kit). In brief, cells were trypsinized under 37℃ and collected and 
centrifuged at 300 × g for 5 minutes. The cell pellet was then washed with cold 1× PBS 3 times. 
Cells were then pelleted again in a 1.5ml Eppendorf tube. By adding 700 µl QIAzol lysis reagent, 
cells were lysed after 5 minutes’ incubation at room temperature. Then 140µl chloroform was 
added and the tube was shaken vigorously for 15 seconds. The tube was centrifuged at 8000 × g at 
4°C 15 min after 3 minutes’ incubation. The upper aqueous phase which contains miRNA was 
transferred into a new collection tube. Then 1.5 volumes 100% ethanol was added and well mixed, 
which was later on put into an RNeasy Mini spin column in a 2 ml collection tube for centrifugation 
at 8000 × g (RT, 1min). The RNeasy Mini spin column which contains miRNAs was then washed 
with 700 µl RWT Buffer (included in the Qiagen kit) once and 500 µl RPE Buffer (included in the 
Qiagen kit) twice. 30-50µl RNase-free water in directly onto the RNeasy Mini spin column 
membrane and miRNAs were then obtained by centrifugation at 8000 × g for 2min. RNA was 
quantified using a spectrophotometer. The quality of isolated miRNA was evaluated by the 
A260/A280 value. 
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3.2.6 The isolation of RNA from cultured cells 
    Total RNA from cells was isolated using RNeasy Mini Kit following the manufacturer’s 
instruction. Briefly, cells were trypsinized under 37℃ and then centrifuged at 300 × g for 5 minutes. 
After 3 times’ wash with 1 × PBS, cells were transferred into a 1.5ml Eppendorf tube and the cell 
pellet was lysed by adding 600 µl RLT Buffer (included in the Qiagen kit). To homogenize the cell 
lysis, it was transferred into the QIAshredder spin column placed in a 2 ml collection and 
centrifuged at 8000 × g for 1min. Thereafter, an equal volume of 70% ethanol was added into the 
2ml tube and mixed well. Then 700µl mixture was transferred into the RNeasy spin column placed 
in a 2 ml collection tube. The RNeasy spin column was centrifuged again at 8000 × g. Total RNA 
that stayed in the spin column was washed with 700µl RW1 Buffer (included in the Qiagen kit) 
once and 500µl RPE Buffer twice (included in the Qiagen kit) by centrifugation at 8000 × g for 1 
min. The spin column was then put into a new 2 ml collection tube and 30-50µl RNase-free water 
was directly added to the spin column membrane. The total RNA was finally precipitated by a 
centrifugation at 8000x g for 1 minute. RNA was quantified using a spectrophotometer. The quality 
of isolated miRNA was evaluated by the A260/A280 value. 
 
3.2.7 SYBR Green quantitative PCR for miRNAs 
3.2.7.1 cDNA synthesis for miRNA RT-PCR 
miScript II RT Kit (Qiagen) was used for the generation of cDNA from the miRNA. The reverse 
transcription reaction was set up by mixing the following setup: 
 
Component Volume/reaction 
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5x miScript HiSpec Buffer 4 μl 
10 × Nucleics Mix  2 μl 
RNase-free water Variable 
miScript Reverse Transcriptase Mix 2 μl 
Template RNA Variable (500ng) 
Total volume 20 μl 
 
An equal amount of miRNA (500ng) from the miRNA sample was added into each reaction at the 
last step. The reagent was then gently mixed and briefly centrifuged. The reverse transcription 
reaction was incubated in the machine (60 minutes’ incubation at 37℃ and 5 minutes at 95℃). 
After the incubation, each tube was diluted with 200µl RNase-free water for later use in RT-PCR 
analysis. The cDNA can be stored in -20℃ for later use. 
  
3.2.7.2 Real time PCR analysis of mature miRNAs 
Expression of mature miRNAs was determined by miScript miRNA PCR Array (Qiagen), and 
normalized using the 2-ΔΔCT method relative to U6-snRNA. For this purpose, 1µl cDNA was added 
in 25 µl reaction in 96-well plate. The reaction consists of the following components: 
 
Component Volume/reaction (96 well) 
2x QuantiTect SYBR Green PCR 
Master Mix 
12.5 µl 
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10 × miScript Universal Primer 2.5 µl 
10 × miScript Primer Assay 2.5 µl 
RNase-free Water RNase-free Water 
Diluted cDNA 1 µl 
Total volume 25 µl 
 
The 96 well plate was briefly centrifuged for 1 minute to remove any bubbles. The reaction was 
then carried out with the following parameters for 40 cycles in StepOne™ Real-Time PCR System 
(Thermo Fisher): 
 
Step Time Temperature 
Initial activation step 15 min 95ºC 
3-step cycling:   
Denaturation 15 s 94ºC 
Annealing 30 s 55ºC 
Extension 30 s 70ºC 
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3.2.8 SYBR Green quantitative PCR for retinoid receptor (RARA, RARB, 
RXRA, RXRB) 
3.2.8.1 cDNA synthesis of retinoid receptor mRNA 
The cDNA was synthesized using QuantiTect Reverse Transcription Kit (Qiagen). For this purpose, 
an equal amount of RNAs (500ng) from each RNA sample was used. The RNA was placed on ice 
and the reverse transcription reaction was initiated with genomic DNA elimination reaction as the 
following recipe: 
 
Component Volume/reaction 
gDNA Wipeout Buffer, 7x 2 µl 
Template RNA Variable (500ng) 
RNase-free water Variable 
Total volume 14µl 
 
The reaction was put directly on the ice after incubation for 2 min at 42℃. 
The reverse transcription master mix was performed on ice according to following: 
 
Component Volume/reaction 
Reverse-transcription master mix  
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Quantiscript Reverse Transcriptase 1 µl 
Quantiscript RT Buffer, 5x 4µl 
RT Primer Mix 1 µl 
Template RNA  
Entire genomic DNA elimination reaction  14 µl 
Total volume 20 µl 
 
The reaction was carried out with the following parameters in a PCR machine (Thermocycler): 
 
Temperature Time 
42℃ 15min 
95℃ 3min 
 
Synthesized cDNA can be stored at -20℃ or directly for real time PCR analysis. 
 
3.2.8.2 Real time PCR of retinoid receptor 
Expression of the retinoid receptor was determined by QuantiFast SYBR Green PCR kit (Qiagen) 
and normalized using the 2-ΔΔCT method relative to GAPDH mRNA. For this purpose, 1µl of cDNA 
synthesized before was added in 25 µl reaction in 96-well plate. The reaction consists of the 
following components: 
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Component Volume/reaction  (96 well plate) 
2x QuantiFast SYBR Green PCR Master Mix 12.5 μl 
10 x QuantiTect Primer Assays  2.5μl 
RNAse-free water 9μl 
Template cDNA 1μl 
Total reaction volume 25μl 
 
The 96 well plate was briefly centrifuged for 1 minute to remove any bubbles. The reaction was 
then carried out with the following parameters in StepOne™ Real-Time PCR System (Thermo 
Fisher): 
 
Step Time Temperature 
PCR initial activation step 5 min 95 ℃ 
Two-step cycling   
Denaturation  10 s 95ºC 
Combined annealing/ extension 30 s  60ºC 
for 40 cycles   
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3.2.9 Transfection of miRNAs 
    Transfection is the process of introduction of new genetic material, DNA or RNA into a 
eukaryotic cell. Here, we use HiPerFect Transfection Reagent (Qiagen) to transfect miRNAs into 
pancreatic cancer cells. Transfection was done following manufacturers’ manual. The initial step 
of transfection of miRNA was to determine optimal transfection conditions of different cells. 
Briefly, 1 × 105 cells were suspended in 0.5 ml growth medium and seeded into one well of a 24-
well plate. Then appropriate amount miRNA and HiperFect Transfection Reagent was added into 
100 µl culture medium without serum. The mixture was vortexed and incubated for 5-10min at 
room temperature to allow the formation of transfection complexes. Transfection was achieved by 
adding the mixture dropwise into each well. The plate was gently swirled and incubated under 
normal growth condition (5% CO2, 37℃, 90% humidity) for 48-72 h. The Pipetting scheme to 
optimize transfection of miRNA is shown in the table below: 
 
Amount (conc.) of miRNA 75 ng 
(10 nM) 
 
75 ng 
(10 nM) 
75 ng 
(10 nM) 
Volume of HiPerFect Reagent 1.5 µl 3 µl 4.5µl 
 
Amount (conc.) of miRNA 37.5 ng 
(5 nM) 
 
37.5 ng 
(5 nM) 
37.5 ng 
(5 nM) 
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Volume of HiPerFect Reagent 1.5 µl 3 µl 4.5µl 
 
Amount (conc.) of miRNA 7.5 ng 
(1 nM) 
 
7.5 ng 
(1 nM) 
7.5 ng 
(1 nM) 
Volume of HiPerFect Reagent 1.5 µl 3 µl 4.5µl 
 
    After the incubation for 48-72 hours, cells were collected and miRNA were isolated with the 
protocol as described before. The level of target miRNA was determined by RT-PCR again 
compared with non-transfected cells. 
 
3.2.10 Protein extraction 
    Cells growing in 24 well-plate were washed with the cold phosphate-buffered saline (PBS) 
buffer three times and lysed in extraction buffer (RIPA buffer) by incubation on ice for 15 min 
(RIPA buffer recipe: 150 mM sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS (sodium dodecyl sulfate), 50mM Tris, pH 8.0). Cell lysis was centrifuged 
for 20 min (12000 × g, 4℃). The supernatant containing the total protein was used for western blot 
or stored at -80℃. 
 
3.2.11 Protein quantification 
    The concentration of the isolated protein was investigated by utilizing the BCA Protein assay 
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(Pierce). This assay is based on the detection of Cu1+ ions by bicinchoninic acid (BCA). Peptide 
bonds in protein can transfer Cu2+ ions into Cu+. In the end, a purple-colored water soluble 
complex was generated which has an absorbance-max at 562nm. The total protein concentration is 
proportional correlated with the color change, which can be measured 
using colorimetric techniques. Briefly, 200µl of AB reagent (50 parts of BCA Reagent A with 1 
part of BCA Reagent B) was mixed with 25µl of the diluted protein in 96 well plate and incubated 
at 37℃ for 1h. The purple color has then developed and the 96 well plate was allowed to cool down 
to room temperature before the measurement. The absorbance of each well at 562nm was measured 
on the plate reader (Spectra Max). The protein concentration of the unknown samples was 
determined by the standard curve of BSA standards.  
 
3.2.12 Protein gel electrophoresis (SDS-PAGE) 
    Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a method widely 
used to achieve a semi-quantitative measurement of target proteins based on the molecular weight. 
The principle is that SDS can denature the protein by binding to their hydrophobic regions, thus 
making them negatively charged. The charged proteins are then loaded on a polyacrylamide gel 
and start to separate when given an appropriate electric field. In combination with Western blotting, 
this method was able to determine the size and relative expression of target proteins among 
different groups. Western blotting is a method to detect the target protein in a PVDF membrane by 
using the specific antibody directed against that target protein. In SDS-PAGE, a stacking gel at the 
top and a separating gel at the bottom was combined. The stacking gel has a large pore size and is 
used to stack proteins at the beginning. The components of each gel were indicated in the following 
table. The separating gel at the bottom was made first and then covered with isopropanol to get a 
horizontal gel surface. Polymerization was allowed for 30 minutes or even longer until a clear 
liquid-gel interface was visible. Then the isopropanol was removed completely and the 4% stacking 
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gel was cast on top of the separating gel. The comb was set into the stacking gel from the top side. 
When the stacking gel had polymerized for nearly another 40 minutes or longer, the complete gel 
complex was immersed in a chamber containing the running buffer. The comb was carefully 
removed, avoiding any scratches of the gel surface. Typically 25-30 μg protein was loaded into 
each well. 5 μg protein standard mix was loaded as the standard marker. The gel was then run at 
120V until the required separation of the marker was obtained. 
 
Recipes for separating gel and stacking gel: 
 
Component Separating Gel Stacking Gel 
 8% 10% 12% 4% 
Distilled Water 9.3 ml 7.9 ml 6.6 ml 6.1 ml 
Acrylamide mix 5.3 ml 6.7 ml 8 ml 1.3 ml 
Tris 5 ml 5 ml 5 ml 2.5 ml 
10% SDS 200 µl 200 µl 200 µl 100 µl 
10% APS 200 µl 200 µl 200 µl 60 µl 
Temed 20 µl 20 µl 20 µl 20 µl 
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3.2.13 Western blotting 
3.2.13.1 Protein transfer 
    The proteins was separated by SDS-PAGE. The gel was then transferred onto a PVDF 
membrane by wet electrophoretic transfer. The membrane was first wet in 100% methanol for 5 
seconds and then equilibrated in transfer buffer. The blot was assembled on a wet blotting apparatus 
in the following order, from the anode to cathode, 1 sponge, 2 Whatman filter papers soaked in 
transfer buffer, PVDF membrane, gel, 2 Whatman filter papers and finally 1 sponge. Transfer of 
proteins was done for 1.5-2 hour by applying stable 200 mA electricity on the apparatus. 
 
TBS 10 × (concentrated TBS) recipe: 24.23 g Trizma HCl/ 80.06 g NaCl Mix in 800 ml ultra-pure 
water, adjust pH to 7.6 with 1mol/L HCl, top up to 1L. 
TBST recipe: 100 ml of TBS 10 × + 900 ml ultra-pure water + 1 ml Tween 20 
 
3.2.13.2 Protein detection 
    The membrane was then blocked in the blocking solution (TBS+5%BSA) for 1 hour at room 
temperature. The membrane was then incubated overnight with the primary antibody diluted 
properly in blocking solution. Following three 10-min washes with TBST buffer (0.1% Tween 20 
in TBS), the blot was incubated for 1 hour at room temperature with the fluorescence-conjugated 
secondary antibody diluted in blocking solution in the dark. After the incubation, the membrane 
was washed 3 × 10minutes with TBST buffer. The protein band was visualized in the Odyssey 
Reader machine.  
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3.2.14 Bioinformatic analysis of the miRNA target 
    To explore the potential target sequence in the 3’UTR of retinoid receptors mRNA, different 
public database website were utilized: 
 
Database Website 
miRNA.org: http://www.microrna.org/microrna/getGeneForm.do 
miRDB: http://www.mirdb.org/miRDB/ 
TargetScanHuman: http://www.targetscan.org/vert_71/ 
     
    Any potential target were selected out if it is predicted by one of these databases.  Specific 
complementary target sequence were recorded. Besides, another public database (miRTarBase) of 
experimentally validated miRNA targets was also utilized to combine with the information of 
already published data. 
 
Database Website 
miRTarBase: http://mirtarbase.mbc.nctu.edu.tw/ 
 
3.2.15 Statistics analysis 
    Statistical analysis was performed using either SPSS software or Graphpad software. Values 
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were presented as mean±SEM. Different statistical programs, such as one-way Anova, Pearson’s 
correlation were utilized depending on specific data types, as indicated in the figures. Significance 
were considered when p-value<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
4. Results 
4.1 Prediction of retinoid receptors targeted by miRNAs  
    The down-regulation of retinoid receptors in PDAC and their correlations with patients’ 
survival was presented in our previous study, indicating that they could function as tumor 
suppressors (Bleul et al., 2015). To investigate the mechanism of down-regulation of retinoid 
receptors, we focus our interests on the regulation function of miRNA family. More and more 
convincible evidence suggests that miRNAs collaborate with classical tumor suppressors and 
oncogenes to functionally regulate key pathways involved in the progress of cellular growth control 
(Lin He & Hannon, 2004). To investigate whether one retinoid receptor is targeted by a specific 
miRNA, the first step is to predict the specific binding sites in the 3’UTR of the retinoid receptor 
mRNA. Therefore, we combined several prediction databases (Targetscan, mirbase, Pictar and 
miRDB, see Materials and methods) to analysis the targeting sites. The analysis reveals that the 
miRNAs, namely miR-138, miR-206, miR-613, miR-9, miR-27a/b, can potentially target retinoid 
receptors. Retinoid receptors and predicted target miRNAs are represented in Table 4. 
 
 
 
Table 4. Predicted retinoid receptors targeted by selected miRNAs. 
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4.2 Investigation of miRNAs target sites in the 3’UTR of retinoid receptors 
    To identify the specific targeting sites, each mRNA of the retinoid receptor was screened for 
complementarity to seed sequences of selected miRNAs. As a result, several 100%-match target 
sequences were found: (1) miR-138 targets at nt330-337 of the RARA-3’UTR; (2) miR-27a and 
miR-27b targets at nt740-747 of the RARA-3’UTR; (3) miR-206 targets at nt22-30 of the RARB-
3’UTR; (4) miR-613 targets at nt21-29 of the RARB-3’UTR; (5) miR-9-5p targets at nt637-644 of 
the RXRA-3’UTR; (6) miR-27a/b-3p targets at nt2818-2826 of the RXRA-3’UTR. Besides, a non-
100%-match target sequence was also identified: miR-27a targets at nt177-196 (see Figure 14).  
 
 
66 
 
Figure 14. Target sequence of selected miRNAs within 3’ UTR of retinoid receptors predicted by integrated database. 
4.3 Investigation of the expression of selected miRNAs in PDAC and HPDE cell 
lines 
    To find out whether there are correlations of selected miRNAs with these retinoid receptors, 
we investigated the basal expression of selected miRNAs in HPDE cell line and 4 PDAC cell lines: 
BxPC-3, Panc-1, DanG, MiaPaCa-2. Expression of mature miRNAs was determined by miScript 
miRNA PCR Array (Qiagen) and normalized using the 2-ΔΔCT method relative to U6-snRNA 
(housekeeping gene for miRNA), as described in the Materials and Methods.  
 
Figure.15 Overview of the miRNA expression in PDAC cell lines and HPDE cell line determined by qRT-PCR. 500 
ng of total RNA extracted from cell line were used to determine miRNAs expression levels by qRT-PCR. All expression 
data were normalized by the U6 expression level and presented as the relative expression level. The relative expression 
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level of each miRNA in HPDE was arbitrarily set as 1.0. The fold changes of miRNA in PDAC cell line compared 
with HPDE cell show a P value of <0.05 (*) or <0.01 (**) in one-way ANOVA. n.s. indicate there is no significant 
difference between the PDAC group compared to HPDE group. 
 
    The miRNAs expression in PDAC cell lines (BxPC-3, Panc-1, DanG, MiaPaCa-2) and HPDE 
cell are shown in Figure 15. As shown in the figure, expression levels of these selected miRNAs 
varied considerably. Specifically, miR-27a increased by nearly 3 and 2 fold changes in BxPC-3 and 
MiaPaCa-2 respectively, compared to the expression level in HPDE cell. In contrast, the expression 
of miR-27a slightly decreases in PanC-1 and DanG (Figure 15).  
    Interestingly, the basal expression of miR-206, miR-613 and miR-138 are significantly 
decreased in PanC-1, DanG and MiaPaCa-2, but not significantly changed in BxPC-3 compared 
to the level in HPDE cell (Figure 15). Besides, miR-9, miR-10a and miR-10b are all high 
expressed in PanC-1 (Figure 15).  For miR-27b, the expression levels increase significantly in 
BxPC-3 and PanC-1 with a fold change of 5 and 1.8, but decrease by 96% percentage in 
MiaPaCa-2 (Figure 15).  
 
4.4 Analysis of retinoid receptor expression in PDAC cell lines  
     Next, we investigated the basal expression of the mRNAs of RARA, RARB, RXRA and 
RXRB in HPDE cell and four different PDAC cell lines: BxPC-3, Panc-1, DanG and MiaPaCa-2. 
Expression of retinoid receptors was determined by RT² Profiler PCR Arrays (Qiagen), and 
normalized using the 2-ΔΔCT method relative to GAPDH mRNA (housekeeping gene for retinoid 
receptors), as described in the Materials and Methods.  
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Figure 16. Overview of the retinoid receptors mRNA expression in PDAC cell lines and HPDE cell line determined 
by qRT-PCR. 500 ng of total RNA extracted from cell line were used to determine mRNAs expression levels by qRT-
PCR. All expression data were normalized by the GAPDH expression level and presented as the relative expression 
level. The relative expression level of target mRNA in HPDE was arbitrarily set as 1.0. The fold changes of mRNAs 
in PDAC cell line compared with HPDE cell show a P value of <0.01 (**) in one-way ANOVA. n.s. indicate there is 
no significant difference between the PDAC group compared to HPDE group. 
 
    The retinoid receptors expression in PDAC cell (BxPC-3, Panc-1, DanG and MiaPaCa-2) and 
HPDE cell are shown in Figure 16. The results indicate that the expression of retinoid receptors 
varied in different cell lines. As showed in Figure 16, expression of RARA significantly decreased 
in BxPC-3, PanC-1 and MiaPaCa-2, while increased in DanG. Similarly, RARB is significantly 
decreased in PanC-1, DanG and MiapaCa-2, as compared to the level in HPDE cell. However, the 
expression of RARB increased with more than 8 times in BxPC-3 than in HPDE cell (Figure 16). 
    In PanC-1 and MiaPaCa-2, there is a significant down regulation of RXRA expression 
compared to in HPDE cell (Figure 16). While RXRB expressions are decreased in all four PDAC 
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cell lines compared to HPDE cell (Figure 16). n.s. indicate there is no significant difference 
between the PDAC cell line and HPDE cell. 
 
4.5 Correlation analysis between selected miRNAs and retinoid receptors 
    Based on the basal expression of selected miRNAs and retinoid receptors in both PDAC cell 
lines and HPDE cell, we next want to find out whether the expression of selected miRNAs 
correlates with the gene expression level of retinoid receptors.  
 
 RARA RARB RXRA RXRB 
miRNA27a -0.8a 
0.104b 
+0.900* 
0.037 
+0.300 
0.624 
-0.600 
0.285 
miRNA206 +0.100 
0.873 
+0.700 
0.188 
+0.900* 
0.037 
+0.300 
0.624 
miRNA613 +0.500 
0.391 
+0.500 
0.391 
+0.900* 
0.037 
+0.700 
0.188 
miRNA138 +0.300 
0.624 
+0.600 
0.285 
+1.000* 
0.000 
+0.400 
0.505 
miRNA9 +0.700 
0.188 
-0.600 
0.285 
0.000 
1.000 
+0.600 
0.285 
70 
 
miRNA10a +0.051 
0.935 
-0.154 
0.805 
+0.154 
0.805 
-0.103 
0.870 
miRNA10b -0.462 
0.434 
+0.359 
0.553 
+0.051 
0.935 
-0.308 
0.614 
miRNA27b +0.000 
1.000 
+0.500 
0.391 
+0.700 
0.188 
+0.100 
0.873 
Table 5. Correlations between expression levels of selected miRNAs and retinoid receptors in HPDE and PDAC 
cell lines.  
a Spearman’s correlation coefficient 
b P Spearman’s rank correlation test 
* Spearman’s correlation coefficient > +0.50 or < −0.50 and P < 0.05 is considered significant 
 
    For this purpose, Spearman’s rank correlation test was performed and the result was presented 
in Table 4. In HPDE cell and PDAC cell lines, expression levels of RARB were positively 
correlated with the level of miRNA27a (Spearman’s correlation coefficient: +0.900 (P = 0.037)). 
Besides, expression levels of RXRA were also shown to be positively correlated with miRNA206, 
miRNA613 and miRNA138 ((Spearman’s correlation coefficient: +0.900 (P = 0.037), +0.900 
(P = 0.037), and +0.990 (P = 0.001), respectively)). However, no other significant correlations 
between these selected miRNAs and retinoid receptors were observed.  
    As is indicated in Table 4, there are significant correlations between specific miRNA and 
retinoid receptors such as the correlation between miR-613 and RXRA, but the correlation 
coefficient reveals that they are positively correlated rather than negatively correlated. From this 
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aspect, we cannot draw the conclusion that there are significant correlations which are 
meaningful for our experiments. Although there are no significant correlations from the result of 
Spearman’s correlation analysis, it does not mean that there are definitely no correlations between 
selected miRNAs and retinoid receptors. One possibility is that although the expression level of 
miRNAs in PDAC cell line is relatively higher than that in HPDE cell, there can be no changes 
of the expression of the target gene in both PDAC cell and HPDE cell. The explanation can be 
that the absolute expression level of miRNAs in the cell is still not enough to cause significant 
changes in the expression of the target gene (See Figure 17). 
 
 
Figure 17. The relative expression of selected miRNAs in PDAC and HPDE cell lines. A-H, relative expression of 
miR-27a, miR-138, miR-206, miR-613, miR-9, miR-10a, miR-10b and miR-27b in PDAC cell lines and HPDE cell. 
All expression data were normalized by the U6 expression level. The expression level of U6 in each cell was arbitrarily 
set as 1.0. The relative level of miRNAs compared to U6 in PDAC cell and HPDE cell is shown. P <0.01 (**) indicate 
there is a significant difference between the miRNAs and U6 expression level. 
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    Despite, we next want to investigate the effect of miR-27a, miR27b and miR9 on the gene 
expression of retinoid receptors due to the following fact: (1) the expression level of miR-27a, 
miR27b, miR9, miR10a and miR10b in PDAC cell lines are significantly higher than that in 
HPDE cell (Figure 15); (2) The absolute expression of miR-27a, miR27b, miR9, miR10a and 
miR10b are not very low or even higher compared to the U6 expression in PDAC cell lines and 
HPDE cell (Figure 17); (3) There are predicted retinoid receptor targets only for miR-27a, 
miR27b and miR9 but not miR10a and miR10b in the prediction database (Table 4).  
 
4.6 Investigation of retinoid receptors expression after the manipulation of   
miRNAs expression 
4.6.1 Investigation of the optimal transfection conditions 
    To investigate the retinoid receptors expression after manipulation of miRNAs, we first 
performed transfection with combinations of different concentration of miRNA mimics with 
transfect reagent in PanC-1 cell and DanG cell, as described in the Material and Methods. 
Transfected cells were then collected for total RNA isolation. 500ng total RNA was then used for 
Real-Time PCR analysis. The relative expression levels of miRNA after transfection were 
calculated compared to the miRNA expression in the cell transfected with negative control 
miRNAs. The results show that for the Panc-1 cell, the combination of 0.15μl miRNA mimics with 
3μl HesPect buffer result in the maximum expression level of the miRNA mimics (Figure 18). For 
DanG cell, the combination of 0.15μl miRNA mimics with 1.5μl HesPect buffer result in the 
maximum expression level of the miRNA mimics (Figure 19). 
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Figure 18. miRNA-9 level detected by RT-PCR in PanC-1 cell after transfection of miRNA mimic. Cells were 
transfected with miRNA mimics. Total RNA were isolated from the cell 48 hours after transfection. 500ng total RNA 
was used for Real-Time PCR analysis. The relative expression levels of miRNA after transfection were normalized 
with the expression of U6 and compared to the negative control (NC) group. The miRNA expression in the NC cell 
was set as 1. 
 
 
Figure 19. miRNA-9 level detected by RT-PCR in DanG cell after transfection of miRNA mimic. Cells were transfected 
with miRNA mimics. Total RNA were isolated from the cell 48 hours after transfection. 500ng total RNA was used for 
Real-Time PCR analysis. The relative expression levels of miRNA after transfection were normalized with the 
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expression of U6 and compared to the negative control (NC) group. The miRNA expression in the NC cell was set as 
1.  
 
4.6.2 Analysis of protein expression of retinoid receptors after miRNA 
transfection 
    Next, we investigated protein expressions of retinoid receptors in PDAC cell after the 
manipulation of miRNAs level. For this purpose, PDAC cell were transfected with miRNA mimics 
and incubated for 48-72 h under normal conditions for cell culture. The whole protein was isolated 
and proceeded with Western Blot analysis, as described in the Material and Methods. Results of 
Western Blot are presented in Figure 20 - 23.  
    After the transfection of miR-9, miR-27a or miR-27b, there are no significant inhibition of 
the expression of retinoid receptors in both PanC-1 cell and DanG cell compared with negative 
control (Figure 20 - 23).     
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Figure 20. Expression of RARa in Panc-1 and DanG cells transfected with miR27a, miR27b or miR9. (A) 25 μg total 
protein extracted from Panc-1 and DanG cell lines were electrophoresed in 10% SDS-PAGE and followed by western 
blotting. The membrane was incubated with rabbit polyclonal anti-RARa antibody as primary antibody and IRDye® 
680CW Goat anti-Rabbit as secondary antibody. GAPDH was used as the loading control; (B) Densitometric values 
of the bands were calculated and normalized with background by using GelAnalyzer 2010 software. Relative intensity 
(i.e. density ratio of target protein/GAPDH) from triplicate experiments are represented as bar diagram, mean ± S.D. 
The data processing was confirmed by 2 person independently. 
 
 
 
Figure 21. Expression of RARb in Panc-1 and DanG cells transfected with miR27a, miR27b or miR9. (A) 25 μg total 
protein extracted from Panc-1 and DanG cell lines were electrophoresed in 10% SDS-PAGE and followed by western 
blotting. The membrane was incubated with rabbit polyclonal anti-RARb antibody as primary antibody and IRDye® 
680CW Goat anti-Rabbit as secondary antibody. GAPDH was used as the loading control; (B) Densitometric values 
of the bands were calculated and normalized with background by using GelAnalyzer 2010 software. Relative intensity 
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(i.e. density ratio of target protein/GAPDH) from triplicate experiments are represented as bar diagram, mean ± S.D. 
The data processing was confirmed by 2 person independently. 
 
 
Figure 22. Expression of RXRa in Panc-1 and DanG cells transfected with miR27a, miR27b or miR9. (A) 25 μg total 
protein extracted from Panc-1 and DanG cell lines were electrophoresed in 10% SDS-PAGE and followed by western 
blotting. The membrane was incubated with rabbit polyclonal anti-RXRa antibody as primary antibody and IRDye® 
680CW Goat anti-Rabbit as secondary antibody. GAPDH was used as the loading control; (B) Densitometric values 
of the bands were calculated and normalized with background by using GelAnalyzer 2010 software. Relative intensity 
(i.e. density ratio of target protein/GAPDH) from triplicate experiments are represented as bar diagram, mean ± S.D. 
The data processing was confirmed by 2 person independently. 
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Figure 23 Expression of RXRb in Panc-1 and DanG cells transfected with miR27a, miR27b or miR9. (A) 25 μg total 
protein extracted from Panc-1 and DanG cell lines were electrophoresed in 10% SDS-PAGE and followed by western 
blotting. The membrane was incubated with rabbit polyclonal anti-RXRb antibody as primary antibody and IRDye® 
680CW Goat anti-Rabbit as secondary antibody. GAPDH was used as the loading control; (B) Densitometric values 
of the bands were calculated and normalized with background by using GelAnalyzer 2010 software. Relative intensity 
(i.e. density ratio of target protein/GAPDH) from triplicate experiments are represented as bar diagram, mean ± S.D. 
The data processing was confirmed by 2 person independently. 
 
    Next, we investigated protein expressions of retinoid receptors in PDAC cell after the 
transfection of miRNAs inhibitors. For this purpose, PDAC cell were transfected with miRNA 
inhibitor and incubated for 48-72 h under normal conditions for cell culture. The whole protein was 
isolated and proceeded with Western Blot analysis, as described in the Material and Methods. 
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Results of Western Blot and the densitometric analysis are presented in Figure 24-25. It shows there 
is no significant changes in the expression of retinoid receptors in both PanC-1 cell and DanG cell 
compared with negative control (Figure 25-26).     
 
 
Figure.24 Expression of retinoid receptors in Panc-1 and DanG cells transfected with anti-miR27a, anti-miR27b or 
anti-miR9. 20 μg total protein extracted from Panc-1 and DanG cell lines were electrophoresed in 10% SDS-PAGE 
and followed by western blotting. The membrane was incubated with rabbit polyclonal antibody (anti-RARa, anti-
RARb, anti-RXRa or anti-RXRb) as primary antibody and IRDye® 680CW Goat anti-Rabbit as secondary antibody. 
GAPDH was used as the loading control. 
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Figure 25. Relative intensity of retinoid receptors expression after the transfection of miRNA inhibitors. Densitometric 
values of the bands were calculated and normalized with background by using GelAnalyzer 2010 software. Relative 
intensity (i.e. density ratio of target protein/GAPDH) from triplicate experiments are represented as bar diagram, mean 
± S.D. The data processing was confirmed by 2 person independently. 
 
    To find out whether these miRNAs are indeed transfected into the cells, MET, an 
experimentally validated target of miR27a, was selected as a positive control (Acunzo et al., 2013). 
The same amount of miRNA27a was transfected PanC-1 and DanG cell with the same procedure, 
as mentioned above. After incubated for 48-72 h under normal conditions, the whole protein was 
isolated and proceeded with Western Blot analysis, as described in the Material and Methods. 
Results of Western Blot are presented in Figure 26. 
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    It showed that transfection of miR27a mimics into PanC-1 and DanG cell lead to a significant 
decrease of MET protein level by Western Blot analysis (Figure 26). 
 
 
 
Figure.26 Expression of MET in Panc-1 and DanG cells transfected with miR27a (A) 25 μg total protein extracted 
from Panc-1 and DanG cell lines were electrophoresed in 10% SDS-PAGE and followed by western blotting. The 
membrane was incubated with rabbit polyclonal anti-MET antibody, mouse polyclonal anti-GAPDH as primary 
antibody and IRDye® 680CW Goat anti-Rabbit and IRDye® 680CW Goat anti-Mouse as secondary antibody. GAPDH 
was used as the loading control; (B) Densitometric values of the bands were calculated and normalized with 
background by using GelAnalyzer 2010 software. Relative intensity (i.e. density ratio of target protein/GAPDH) from 
triplicate experiments are represented as bar diagram, mean ± S.D. The data processing was confirmed by 2 person 
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independently. 
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5. Discussion 
    PDAC is one of the most deadly cancers, with the death ranking fourth among cancer-related 
deaths. Despite emerging progression of the understanding of cancer in past decades, PDAC 
remains the major burden of human health. The extremely poor prognosis results largely from the 
diagnosis of cancer at advanced stages. Frequently perineural and vascular local growth and 
invasion of PDAC cell usually lead to the distance metastasis at an early stage. Most conventional 
treatment strategies, like chemotherapy, radiotherapy and molecular immune therapy, experienced 
remarkable resistance when applied in treating PDAC. PDAC is characterized by multiple genetic 
and epigenetic aberrations and the unique dense tumor microenvironments, which result in the 
heterogeneity of PDAC and variation of treatment outcomes (Jorg Kleeff, 2016). 
 
5.1 Aberrant level of retinoid receptors in cancer 
    As discussed in the Introduction, all-trans-RA derives from the metabolism of vitamin A and 
functions through binding to the retinoid receptors. A successful case of cancer treatment using all-
trans-RA is well known in acute promyelocytic leukemia (APL). In APL patients, the RARA gene 
is fused mainly to promyelocytic leukemia (PML) gene which generates abnormal PML-RARA 
fusion protein. The fused protein complex increases HDACs level and related DNA 
methyltransferase complexes, leading to the epigenetic silencing of retinoid-regulated genes, 
including those involved in the regulation of myeloid differentiation and proliferation (Di Croce, 
2005; Freemantle, Spinella, & Dmitrovsky, 2003). 
    In other cancer types, the retinoid signaling pathway is frequently attenuated in tumorous 
tissue versus the surrounding normal epithelial tissue. Besides, RARA, RARB and RARγ are 
reported to have tumor-suppressor effects in various cancer (Farias et al., 2002; Chen, Goyette, & 
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Lohnes, 2004; Treuting et al., 2002). For instance, in squamous cell carcinoma cells, RARB 
function as a key mediator of cell growth inhibition (Le, Dawson, Soprano, & Soprano, 2000). 
Restoration of RARB expression in breast cancer cells can restore the ability of RA to induce both 
growth arrest and apoptosis (Seewaldt, Johnson, Parker, Collins, & Swisshelm, 1995). Similarly, 
thyroid cancer cells expressing both RARB and RXRγ show significant growth suppression when 
treated with retinoids (Haugen et al., 2004). 
    In fact, different retinoid receptor subtypes were dsyregulated in a range of cancer types, 
resulting in a decreased efficacy or the failure of comprehensive therapy with retinoid (Pawlyn et 
al., 2016; Suh et al., 2002; Y. Wang et al., 2016; Xue & Lito, 2016). RARA was also demonstrated 
to be expressed with higher level in differentiated, estrogen receptor (ER)-positive (ER+) 
mammary carcinoma cells compared with undifferentiated, estrogen-independent, ER-negative 
(ER−) cells, which were responsible for the response to retinoid therapy (Schneider, Offterdinger, 
Huber, & Grunt, 2000).  
    In PDAC, global gene expression has also been investigated in PDAC tissues compared to 
normal pancreas. Totally 62 genes have been reported to be significantly down-regulated with more 
than 2 fold changes in PDAC tissues, compared to that in normal pancreas. Moreover, 140 
significantly up-regulated genes were also identified in PDAC tissues (Schneider et al., 2000; Suh 
et al., 2002) (GSE28735, GSE85589). These abnormal expression levels of genes could form 
complex networks regulating the tumorigenesis and tumor metastasis. 
5.2 Mechanism of aberrant level of retinoid receptors in PDAC 
    In consistent with our previous study, we also showed in this study that retinoid receptors in 
PDAC cell were markedly down-regulated compared to the normal pancreatic cell. The mechanism 
of the down-regulation of the retinoid receptor in cancer could be the following possibilities: (1) 
the mutation or deletion of retinoid receptor gene; (2) the transcriptional repression; (3) the post-
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transcriptional repression. The fact that the retinoid receptor genes are not mutated in the majority 
of human cancer specimens indicates that epigenetic events could be involved. Studies have 
reported that RARB can be repressed by the hypermethylation of the promoter of RARB gene and 
histone deacetylation in some types of cancer, resulting in the associated resistance to the growth 
inhibitory effects of RA in some cancer types (Cristiano et al., 2016; Kim, Kim, Park, & Kim, 2016; 
M. F. Lee, Hsieh, Huang, & Li, 2016; Long et al., 2016; Schneider, Offterdinger, Huber, & Grunt, 
2000; Sirchia et al., 2000; Sirchia et al., 2002; S. Yang et al., 2016). Interestingly, Song et al 
reported another possibility that the carcinogen existing in tobacco smoke and environmental 
pollution, Benzo Pyrene Diol Epoxide (BPDE), can inhibit expression of the specific retinoid 
receptors, such as RARB2 gene. In their study, BPDE was able to inhibit RARB2 by methylation 
in a time-dependent manner in esophageal cancer cells (Song et al., 2005). Besides, the RARB2 
was found to be a polycomb group target, providing another manner of epigenetic silencing of this 
tumor-suppressor gene (Bracken, Dietrich, Pasini, Hansen, & Helin, 2006). However, whether the 
loss of retinoid receptors expression in cancer cell drives the initiation of tumor formation or the 
aberrant level of these receptors is the outcome of cancer progression is not well determined (Liu 
et al., 1996; Seewaldt, Johnson, Parker, Collins, & Swisshelm, 1995).  
    Aberrant retinoic acid signaling in stromal cell has also been shown to act on the PDAC cell. 
RA was shown to be able to induce quiescence and reduce motility of PSCs, leading to reduced 
proliferation and increased apoptosis of surrounding PDAC cells (Froeling et al., 2011).  
5.3 Aberrant expression level of miRNA in PDAC 
    miRNA is produced from the transcript pre-miRNA (longer primary transcripts), which is 
generated mainly by RNA polymerase II (Cai, Hagedorn, & Cullen, 2004; Y. Lee et al., 2004). 
miRNAs genes usually locate in introns of protein-coding genes. Usually, several miRNAs genes 
that are arranged in clusters within the genome can be transcribed into one pri-miNRA, which will 
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be further processed into several miRNAs functioning as a regulator group (Rodriguez, Griffiths-
Jones, Ashurst, & Bradley, 2004). 
    The biogenesis of miRNA comprises four main processes: (1) Microprocessor complex 
(Drosha/DGCR8) liberates a hairpin-sturcture miRNA precursor (pre-miRNA). (2) Export receptor 
transport pre-miRNAs to the cytoplasm. (3) Dicer cleaves the pre-miRNA molecule to become a 
short-lived double stranded intermediate. (4) The double strand was diced into two strands and one 
strand becomes the mature miRNA. miRNA expression can be regulated transcriptionally and post-
transcriptionally at the level of RNA processing (van Kouwenhove et al., 2011). In addition, the 
degradation of miRNAs can be regulated both by proteins and by cell divisions, during which the 
pool of miRNAs was diluted if the rate of miRNAs production is less than the sum of dilution and 
degradation (Grosshans & Chatterjee, 2010). For example, the tumor suppressor p53 can induces 
the transcription of miR-34 family members, which in turn inhibit factors like Bcl2 and Cdk4/6, 
being important for cell proliferation and survival (Chang et al., 2007; L. He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007). 
    Besides, miRNAs expression pattern can be affected at different levels. Some miNRAs can 
be strongly induced by stimuli like LPS (Androulidaki et al., 2009; O'Connell, Chaudhuri, Rao, & 
Baltimore, 2009). Interestingly, one study has shown that despite that specific miRNAs can be up-
regulated in cancer, global miRNAs are usually down-regulated in human malignancies through 
several mechanisms. For instance, Sun et al report that Erk activation can decrease expression of 
miRNAs through phosphorylating exportin-5 (Sun et al., 2016). Similarly, Martello et al identify 
that in breast cancer, miR-103/107 attenuates miRNA biosynthesis by targeting Dicer (Martello et 
al., 2010), a key factor in miRNA production. 
    Thus, disease-related changes of miRNA expression should include the understanding of both 
global expression and temporal expression pattern, particularly when the phenotype could be 
induced by multiple biological process and various stimuli. 
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5.4 miRNA profiles by microarray in PDAC 
    In general, the whole genome miRNA profile provides high-through data demonstrating that 
dysregulated miRNA signatures are indeed found in many cancers (Calin & Croce, 2006). For 
example, several groups have applied microarray in PDAC specimens to investigate the expression 
alteration of miRNAs as well as global RNA transcriptome. They identified the change of miRNAs 
landscape in PDAC tissue compared to either adjacent normal tissue or normal pancreas. For 
example, a study involved in 7 PDAC patient specimens and 5 non-neoplastic pancreases have 
revealed that totally 91 significantly up-regulated miRNAs and 109 down-regulated miRNAs with 
at least 1.5 fold changes are identified in PDAC. Among them, hsa-miR-135b ranks at the top of 
the up-regulation list, with a 13 fold changes’ increase. While has-miR-216a decreased with 36 
fold changes in PDAC tissue compared with the non-neoplastic pancreas. The selected miRNAs in 
our work, namely miR-27a, miR-27b, miR-10 and miR-9, are up-regulated while miR-613 and 
miR138 experienced no significant up-regulation in PDAC tissue compared with normal pancreas.  
    Other research groups also investigated the changes of miRNAs levels in the short-overall-
survival group compared with long overall survival group. They identified differentially expressed 
miRNAs between the two groups (Giovannetti et al., 2012). Despite the alteration of miRNAs 
expression, RNA transcriptome in PDAC are also widely focused.   
    Some of the dysregulated miRNAs are meaningless, while others can play important role in 
regulating tumorigenesis and metastasis. Hence, these functional miRNAs are defined as the tumor 
suppressor or onco-miRNA. For instance, miR-21 was found to be unregulated and serve as 
oncogenic miRNAs in various malignancies, such as glioblastoma, colorectal, breast and PDAC 
(Calin & Croce, 2006). In contrast, miR-146a is decreased as a result of gene deletion of 
chromosome 5 in the malignant hematopoietic progenitor cells in myelodysplastic syndrome 
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(Boldin et al., 2011; Calin & Croce, 2006; Zhao, Rao, O'Connell, Garcia-Flores, & Baltimore, 
2013). However, not all dysregulated miRNAs are involved in the pathogenetic process or even to 
be functional. In general, cancer phenotypes induced by overexpression of miRNAs seem to be 
more common than those generated by loss-of-function. This feature may be explained by the fact 
that miRNAs can only function in a transcriptional program under given condition. Hence, miRNA 
gain of function in a cell type could repress target genes that are not properly repressed, while the 
loss of function would restore the functions in cells where target genes and corresponding miRNA 
of interest are concurrently expressed. This indicates that gain and loss-of-function of miRNA 
should be investigated in the appropriate cell types and the appropriate biological system.   
 
5.5 The regulation of retinoid receptors by microRNAs in PDAC 
    Regulation of retinoid receptor genes in post-transcriptional level can also contribute to the 
deregulation of the retinoid receptor in PDAC cancer. Among these mechanisms, miRNA serves 
as one major pattern to regulate up to 30% of protein-coding gene in mammals. Regulation by 
miRNAs results in the destabilization of target mRNA, translational repression and even activation 
(Huntzinger & Izaurralde, 2011). 
    In this study, we aimed to figure out up-regulated miRNAs which could target retinoid 
receptor in PDAC cell lines. We showed the selected up-regulated miRNAs (miR27a, miR27b and 
miR9) were found not to be associated with the down-regulation of retinoid receptors. However, 
the high expression of miR27, miR-21and miR-23a in PDAC patients is associated with aggressive 
tumor behavior and poor survival after PDAC resection (Frampton et al., 2014). Specifically, miR-
27a was found to target BTG2, ZBTB10, Spry2 which are associated with cancer survival, growth 
and angiogenic responses in PDAC. From their study, they concluded that the triple combination 
of miR-21/23a/27a could be a prognosis factor of PDAC (Frampton et al., 2014). Besides, the 
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combination of serum miR-27a and CA19-9 in peripheral blood mononuclear cells could help 
diagnose PDAC (Wang et al., 2013). Those evidence are inconsistent with our results that miR-27a 
is significantly up-regulated in PDAC cell lines. For the down-regulation of retinoid receptors in 
PDAC, Pettersson et al have shown that activation of RAR could cause apoptosis in PDAC cells 
(Pettersson et al, 2002). Similar result was also obtained by Tsujie et al that activation of RXRA 
involved pathway could inhibit the growth of PDAC cells (Tsujie et al, 2003). These results match 
our previous study about the down-regulation of retinoid receptor in PDAC. Interstingly, Tombolan 
and his colleges demonstrate that miR-27a is implicated in tumorgenesis by targeting the RARA 
and RXRA in 293T cell line (one kind of rhabdomyosarcomas cell) (Tombolan et al, 2015). This is 
possible because specific miRNAs could have different effect in specific cell types or pathological 
context. The specific genes that could be regulated by miRNAs in one cell type is largely dependent 
on the whole transcription of that particular cell under given conditions, as discussed in the 
Introduction. 
RARA   RARB RARg RXRA RXRB 
hsa-miR-125a-5p 
hsa-miR-218-5p 
hsa-miR-615-3p 
hsa-miR-138-5p 
hsa-miR-6780a-5p 
hsa-miR-6779-5p 
hsa-miR-3689c 
hsa-miR-3689b-3p 
hsa-miR-3689a-3p 
hsa-miR-30b-3p 
hsa-miR-16-2-3p 
hsa-miR-30c-5p 
hsa-miR-15a-5p 
hsa-miR-16-5p 
hsa-miR-33a-3p 
hsa-miR-15b-5p 
hsa-miR-195-5p 
hsa-miR-424-5p 
hsa-miR-497-5p 
hsa-miR-545-5p 
hsa-miR-182-5p 
hsa-miR-124-3p 
hsa-miR-335-5p 
hsa-miR-320c 
hsa-miR-34c-5p 
hsa-miR-10b-5p 
hsa-miR-423-3p 
hsa-miR-128-3p 
hsa-miR-574-3p 
hsa-miR-486-3p 
hsa-miR-7106-5p 
hsa-miR-4734 
hsa-miR-4532 
hsa-miR-596 
hsa-miR-3940-3p 
hsa-miR-3692-3p 
hsa-miR-3180 
hsa-miR-4467 
hsa-miR-6077 
hsa-miR-8072 
hsa-miR-3960 
hsa-miR-6732-5p 
hsa-miR-6805-5p 
hsa-miR-6794-5p 
hsa-miR-4716-3p 
hsa-miR-4524b-3p 
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hsa-miR-1273h-5p 
hsa-miR-519e-5p 
hsa-miR-515-5p 
hsa-miR-6778-5p 
hsa-miR-1233-5p 
hsa-miR-6780b-5p 
hsa-miR-4725-3p 
hsa-miR-4271 
hsa-miR-6799-5p 
hsa-miR-5196-5p 
hsa-miR-7106-5p 
hsa-miR-4747-5p 
hsa-miR-6797-5p 
hsa-miR-1249-5p 
hsa-miR-6133 
hsa-miR-6130 
hsa-miR-6129 
hsa-miR-6127 
hsa-miR-4510 
hsa-miR-4419a 
hsa-miR-605-3p 
hsa-miR-3925-3p 
hsa-miR-766-3p 
hsa-miR-194-3p 
hsa-miR-6783-5p 
hsa-miR-4307 
hsa-miR-6792-5p 
hsa-miR-6838-5p 
hsa-let-7c-5p 
hsa-miR-548c-3p 
hsa-miR-548x-3p 
hsa-miR-548j-3p 
hsa-miR-548aq-3p 
hsa-miR-548am-3p 
hsa-miR-548aj-3p 
hsa-miR-548ah-3p 
hsa-miR-548ae-3p 
hsa-miR-578 
hsa-miR-6817-5p 
hsa-miR-4769-3p 
hsa-miR-1976 
hsa-miR-6747-3p 
hsa-miR-4722-3p 
hsa-miR-6727-3p 
hsa-miR-660-3p 
hsa-miR-4667-3p 
hsa-miR-4258 
hsa-miR-2681-5p 
hsa-miR-3180-5p 
hsa-miR-7702 
hsa-miR-525-5p 
hsa-miR-520a-5p 
hsa-miR-4724-3p 
hsa-miR-488-5p 
hsa-miR-6782-3p 
hsa-miR-320e 
mmu-miR-677-5p 
mmu-miR-466m-5p 
mmu-miR-669m-5p 
mmu-miR-466h-5p 
mmu-miR-466j 
hsa-miR-6083 
hsa-miR-6754-3p 
hsa-miR-412-3p 
hsa-miR-6756-3p 
hsa-miR-3127-3p 
hsa-miR-6769a-3p 
hsa-miR-197-3p 
hsa-miR-346 
hsa-miR-335-5p 
hsa-miR-26b-5p 
hsa-miR-484 
hsa-miR-92a-3p 
hsa-let-7b-5p 
hsa-miR-573 
hsa-miR-6851-5p 
hsa-miR-3616-5p 
hsa-miR-3689d 
hsa-miR-298 
hsa-miR-7854-3p 
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Table 6. Experimentally validated miRNAs that target retinoid receptors in all human cell types. 
 
    As PDAC is a disease involved with complex and dynamic molecular networks, global gene 
and miRNA research and integrated analysis combining genomic and bioinformatics could be 
applied to elucidate the complicated mechanism in tumor heterogeneity, tumorigenesis, metastasis 
and chemo-radiotherapy resistance. 
 
hsa-miR-4756-5p 
hsa-miR-4739 
hsa-miR-1321 
hsa-miR-940 
hsa-miR-6893-5p 
hsa-miR-3714 
hsa-miR-6808-5p 
hsa-miR-5002-3p 
hsa-miR-4795-5p 
hsa-miR-3158-5p 
hsa-miR-509-5p 
hsa-miR-509-3-5p 
hsa-miR-4418 
hsa-miR-6891-5p 
hsa-miR-3173-3p 
hsa-miR-4278 
hsa-miR-6885-5p 
hsa-miR-328-5p 
hsa-miR-4697-5p 
hsa-miR-4488 
hsa-miR-1237-5p 
hsa-miR-3196 
hsa-miR-6816-5p 
hsa-miR-3180-3p 
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